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ABSTRACT 
This dissertation is dedicated to the research and investigation of novel enzymes and the 
methods used to study them, with physiological roles ranging from isoprenoid biosynthesis to 
neurotransmitter production.  Using a combination of bioinformatics, recombinant cloning, 
enzymology, and proteomics, we have contributed to the understanding and exploration of 
several human illnesses, including malaria, cancer, and endocrine dysfunction.    
Our first project involved studying the enzymes responsible for N-acylarylalkylamide 
biosynthesis in Bombyx mori. Very little is known how these potent signaling molecules are 
produced in vivo, however, one possible pathway is the direct conjugation of an acyl-CoA to a 
corresponding arylalkylamide by the enzyme  arylalkylamine N-acyltransferase (AANAT).  In 
insects, this enzyme is responsible for controlling melanism, the inactivation of biogenic amines, 
the sclerotization of the insect cuticle, photoperiodism, and the penultimate intermediate in the 
production of melatonin.  We studied a pair of AANAT enzymes from B. mori: Bm-AANAT and 
Bm-AANAT3.  The former was found to catalyze the direct formation of long-chain 
acylarylalkylamines (only the second enzyme discovered to do such chemistry), while the latter 
exhibited potent inactivation of several amines through acetylation.  We conducted a full kinetic 
characterization of Bm-AANAT3, including double-reciprocal plots, pH-rate profiling, dead-end 
inhibition, and the construction of mutants to elucidate catalytically-relevant amino acids.  Our 
hope is that new insights and discoveries on these enzymatic pathways in model organisms will 
yield novel molecular targets for human health and disease. 
xi 
 
We then developed an innovative, microwave-assisted synthesis of a binding-based probe 
capable of enriching proteins that bind adenine ribose derivatives (AdoRs).  We employed this 
probe in activity-based protein profiling studies to qualitatively assess the AdoR-binding 
proteome in three bacterial cell lines from the genus Bacillus.  This proof of concept experiment 
demonstrated a unique subset of proteins distinctive to each species, and confirmed the efficacy 
of the probe tagging and subsequent enrichment.  This technology can be used in clinical 
applications for the detection and identification of cancerous biomarkers. 
Finally, we successfully truncated and recombinantly-expressed 1-deoxy-D-xylulose-5-
phosphate synthase (DXS) from both P. vivax and P. falciparum.  We elucidated the order of 
substrate binding for both of these TPP-dependent enzymes using steady-state kinetic analyses, 
dead-end inhibition, and intrinsic tryptophan fluorescence titrations.  Both enzymes adhere to a 
random sequential mechanism with respect to binding of both substrates: pyruvate and D-
glyceraldehyde-3-phosphate.  These findings are in contrast to other TPP-dependent enzymes, 
which exhibit classical ordered and/or ping-pong kinetic mechanisms.  A better understanding of 
the kinetic mechanism for these two Plasmodial enzymes could aid in the development of novel 
DXS-specific inhibitors that might prove useful in treatment of malaria. 
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CHAPTER ONE: 
INTRODUCTION 
 
1.1 An Introduction to Fatty Acid Amides 
Ironically, the birth of fatty acid amide research originated from studies pertaining to an 
illegal plant, cannabis.  Cannabis has been cultivated by a multitude of civilizations spanning 
several millennia, where it has been used for medicine, textiles, recreation, religious rituals, and 
even food.[1]  However, at the turn of the century, access to the plant was limited through federal 
regulations, and became fully criminalized in 1970 under the Comprehensive Drug Abuse 
Prevention and Control Act.[2]  The medicinal use of cannabis sharply declined as alternatives 
were discovered, such as morphine and aspirin.[3] However, as the stigma of the drug has faded 
in recent years, renewed interest in cannabis has fostered novel research endeavors for 
therapeutic and clinical applications.[4]  At current (2015), 23 states and Washington D.C. have 
legalized cannabis for medical purposes, two states (Colorado and Washington) have fully 
legalized its use for recreational purposes, and seven more states have pending legislation 
regarding its deregulation. 
The first psychoactive component of cannabis to be isolated and elucidated was (-)-Δ9-
tetrahydrocannabinol (or more commonly known as “THC”) by the Mechoulam group in 1964 
(Figure 1.1A).[5]  It was not until 1988 that the Howlett group discovered the mammalian brain  
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Figure 1.1 The molecular structures of (A.) Δ9-tetrahydrocannabinol and (B.) Anandamide. 
 
receptor for THC, the cannabinoid receptor 1 (CB1),
[6] followed by the cannabinoid receptor 2 
(CB2) in 1993.
[7]   After the identification of these receptors, it was predicted that an endogenous 
ligand must exist in the mammalian brain.  Shortly thereafter, the first CB1 ligand, anandamide 
(or N-arachidonoylethanolamine, Figure 1.1B), was discovered from porcine brain.  This 
discovery ushered in a new era of studying endocannabinoids and fatty acid amides as potent 
cell-signaling molecules.  Anandamide is implicated in a variety of biophysical phenomena in 
mammals including memory, sleep, locomotion, pain perception, body temperature regulation, 
and appetite.[8-10]  These physiological processes occur when anandamide binds to the CB1 and 
CB2 receptors, as well as the transient receptor potential vanilloid type I (TRPV1) receptors.
[11]  
The biosynthetic pathway of this compound has been extensively studied; yet, for all we have 
learned about anandamide, it only comprises ~10% of the long-chain N-acylethanolamines found 
in the brain (which is only one type of fatty acid amide among dozens!).[12]  As greater numbers 
of these long-chain fatty acid amides were discovered, they were subsequently classified into 
different families: primary fatty acids, N-acyl amino acids, N-acylglycines, N-acylethanolamines, 
N-acylarylalkylamides, N-monoacylpolyamides, and N-acyltaurines.  Examples of these 
compounds are detailed in Table 1.1, while Figure 1.2 shows the general structure of fatty acid 
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amides.  The focus of this dissertation will be the study of the N-acylarylalkylamides, which are 
further discussed in sections 1.2 and 1.3.  
 
   
 
 
Figure 1.2 General structure of fatty acid amides. 
 
Table 1.1 Examples of each fatty acid amide family.a,b 
Fatty Acid Amide Family Structure 
Primary fatty acid amides 
 
N-acyl amino acidsc 
 
N-acylglycines 
 
N-acylethanolamines 
 
N-acylarylalkylamidesd 
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N-monoacylpolyamidese 
 
N-acyltaurines 
 
aR1 represents alkyl groups of varying lengths, depicted in red. 
bBiogenic amines are colored blue, and are conjugated to the acyl group through an amide bond. 
cR2 constitutes various side chains of amino acids 
dThe N-acylarylalkylamide depicted is N-acyltryptamine 
eThe N-monoacylpolyamide shown is N-acylcadaverine 
 
 
At present, most fatty acid amides have no defined neurological function, their 
biosynthetic pathways have not been entirely elucidated, and the majority of their receptors 
remain undiscovered.[12]  Many speculate these molecules must serve some biological function, 
since the brain invests substantial amounts of energy into their production.[13]  Significant 
research remains to identify all of the biologically feasible fatty acid amides, and to elucidate 
their biosynthetic pathways.  Our lab continues to vigorously add to these discoveries, with the 
recent identification of various long-chain N-acylarylalkylamides in D. melanogaster (including 
N-acyldopamines and N-acylserotonins),[14] which is surprising since it is suggested no 
cannabinoid receptors exist in fruit flies.[15]   
In addition to the discovery of these various metabolites, our lab has sought to investigate 
a number of enzymes possibly implicated in the generation of fatty acid amides.[16-18]  Two 
potential pathways are commonly attributed to the biosynthesis of the long-chain N-
acylarylalkylamides in vivo, the first being the direct condensation of a fatty acid to a biogenic 
amine by fatty acid amide hydrolase, or FAAH (also known as oleamide hydrolase and 
anandamide amidohydrolase; see Figure 1.3A).   
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Figure 1.3. Proposed biosynthetic enzymes in the production of long-chain N-
acylarylalkylamides. (A.) Fatty acid amide hydrolase (B.) N-acyltransferase 
 
This enzyme is a member of the serine hydrolase family, and displays both esterase and amidase 
activity.[19-20]  Evidence of this pathway was evaluated by the Walker group for FAAH’s role in 
N-arachidonoyldopamine biosynthesis.[21]  In this study, a FAAH inhibitor was fed to FAAH 
knockout rats while the level N-arachidonoyldopamine and anandamide were evaluated; 
anandamide was selected because it is a known FAAH substrate that is hydrolyzed to 
ethanolamine and arachidonic acid.  When compared to control rats, the levels of anandamide 
increased while levels of N-arachidonoyldopamine decreased, which suggests N-
arachidonoyldopamine biosynthesis is directly correlated to FAAH activity.  It was theorized that 
FAAH functions to either (a) directly catalyze the condensation of dopamine and arachidonic 
acid to N-arachidonoyldopamine, or (b) participates in the liberation of arachidonic acid by 
hydrolysis of anandamide which is then shuttled into different pathways such as N-
acylarylalkylamide biosynthesis.[21]  As a follow up, the researchers then evaluated recombinant 
FAAH to determine whether it is a biosynthetic or degenerative enzyme for the production of  N-
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arachidonoyldopamine.  They incubated FAAH with anandamide and deuterated dopamine, and 
assayed the evolution of deuterated N-arachidonoyldopamine over 30 minutes.  Their theory was 
FAAH would first catalyze the hydrolysis of anandamide to arachidonic acid, which would then 
subsequently serve as a substrate for the condensation with dopamine to form the N-
arachidonoyldopamine.[21]  What they discovered was that N-arachidonoyldopamine biosynthesis 
was 180-fold less than the Vmax of the FAAH catalyzed hydrolysis of anandamide; thus, 
arachidonic acid and dopamine are poor substrates for a possible FAAH-catalyzed condensation 
reaction. FAAH is unlikely the biosynthetic enzyme of this pathway since several of the long-
chain N-acylarylalkylamides (primarily the N-acylserotonins) function as inhibitors to its 
enzyme-catalyzed hydrolysis reaction.[22]  A more likely scenario is that FAAH functions to 
degrade and liberate fatty acids, which are then utilized in other fatty acid amide biosynthetic 
pathways. 
The second proposed pathway of N-acylarylalkylamide biosynthesis involves the direct 
acylation of a biogenic amine through an activated fatty acid (in the form of an acyl-CoA), 
facilitated by an N-acyltransferase (NAT) enzyme (Figure 1.3B).  This pathway is more 
thermodynamically favorable over the FAAH-catalyzed reaction, since a thioester is more 
susceptible to nucleophilic attack by a neutral amine.  Such a reaction has been well 
characterized for the N-acetylation of serotonin in the penultimate step of melatonin 
biosynthesis, catalyzed by arylalkylamine N-acetyltransferase (AANAT; also commonly referred 
to as serotonin N-acetyltransferase, or SNAT).[23-28]  Since FAAH is a poor candidate for 
catalyzing this reaction, it is thought that a group of unidentified AANAT or AANATL enzymes 
with specificity for long-chain acyl-CoA substrates could be the biosynthetic enzyme for the 
production of long-chain N-acylarylalkylamides.  The Hunt group recently identified a NAT 
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enzyme, glycine N-acyltransferase 2 (GLYATL2), which catalyzes the formation of long-chain 
N-acylglycines in vitro.[29]  In addition, Dempsey et al, have demonstrated that an AANAT from 
D. melanogaster is capable of producing long-chain N-acylserotonins from long-chain acyl-CoA 
substrates.[16]  The focus of Chapter 2 of this dissertation pertains to the study of a pair of 
AANAT enzymes from Bombyx mori, one of which shows evidence of catalyzing the formation 
of long-chain N-acyltryptamines, among other biogenic amines.  Additional research is required 
to confirm or exclude this chemical step in the biosynthesis of other long-chain N-
acylarylalkylamides. 
 
1.2 Historical Perspectives of Arylalkamine N-acetyltransferase 
Arylalkamine N-acetyltransferase (AANAT) has been exhaustively studied in vertebrates 
due to its role as the penultimate enzyme in the biosynthetic pathway of melatonin production. 
[23-28]  In particular, this enzyme has key implications in daily and seasonal timing for metabolic 
activity and developmental modifications, thus its moniker as the “timezyme.”   Locations of 
AANAT expression constitute the pineal gland, retina, the photosensitive parietal eyes, and the 
Harderian gland of tetrapods.[30]  The gastrointestinal tract of mammals may also prove to be a 
site of expression due to massive amounts of melatonin detected, with nearly 400 times the 
concentration as compared to the pineal gland.[31]  Melatonin is involved in a litany of 
physiological processes including circadian entrainment, immune function, blood pressure 
regulation, oncogenesis, as well as controlling motility, inflammation, and pain in the 
gastrointestinal tract. [32-33] 
AANAT belongs to the GCN5-related N-acetyltransferase (GNAT) superfamily,[34] and 
can be classified as either vertebrate (vt) AANAT or non-vertebrate (nv) AANAT based on 
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homology similarities. According to sequence approximations, AANATs have been identified in 
Gram-positive bacteria, certain lower plants, algae, fungi, annelida, placosoa, cephalochordates, 
and vertebrates; however, other published genomes are devoid of this class of enzyme, including 
nematodes and higher plants.[35]  Hypotheses abound that a horizontal gene transfer from bacteria 
to an ancestor of vertebrates caused the evolution of this class of enzyme, since the homologs in 
bacteria, green algae, and fungi lack regulatory sequences found in vtAANAT (as well as lacking 
introns).[36]  It is also thought that the emergence of the vtAANAT timezyme greatly accelerated 
evolution, aiding substantially in reproductive success. 
Since this enzyme is responsible for major neurotransmitter metabolism, it acts as an 
extensive regulator in a multitude of physiological functions, developmental phases, metabolism, 
behavior, and reproduction.  Higher vertebrates possess one gene for AANAT, however, multiple 
known acetylases function as xenobiotic enzymes: seven in cephalochordates and three in 
humans.[37-38]  AANAT transfers an acetyl moiety to 5-hydroxytryptamine (serotonin) and 
controls periodic alterations of circulating melatonin in boney vertebrates (Figure 1.4).[39] 
 
 
 
 
Figure 1.4 The synthesis of melatonin from serotonin, wherein AANAT is the penultimate 
enzyme in the pathway.  
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In mammals, the suprachiasmatic nucleus (SCN) acts as a circadian pacemaker (CPM) 
which collects light signals from the retina, and directly influences pineal melatonin biosynthesis 
as an output.[40]  The rhythmic pattern of activity of the melatonin pathway (i.e., higher 
concentration at night and a low level during the day) is conserved among vertebrates, congruent 
with this hormone’s role as the time-keeper molecule. 
 
1.3 Insect-type AANAT and Associated Biogenic Amines 
AANATs perform diverse roles in physiological and behavioral regulation in insects and 
arthropods. Insect AANAT (iAANAT) is involved in the suppression of black pigmentation 
(known as melanism), as well as sclerotization of the cuticle by N-acetylating amines to provide 
reactive quinones for linking chitin and arthropodins.[41-43]  iAANAT also inactivates biogenic 
amines such as dopamine, serotonin, octopamine, tryptamine, and norepinephrine by N-
acetylation (arylalkylamine + acetyl-CoA → N-acetylarylalkylamine + CoA-SH). These 
arylalkylamines have been suggested to act as potent neurotransmitters, neurohormones, and 
neuromodulators through their binding to specific receptors.[44-46]  This is in stark contrast to the 
metabolic pathways of neurotransmitter monoamines in vertebrates, in which these compounds 
are mainly metabolized by monoamine oxidases (MAO1 and 2).  In arthropods, MAO activity is 
limited or nonexistent, and the amines are catabolized primarily by NATs instead.[47]  In 
addition, iAANAT has been found to control developmental events and photoperiodism via 
melatonin in certain species: orally-administered melatonin synchronizes circadian locomotor 
rhythms of the house cricket, Acheta domesticus,[48] and stimulates the release of a 
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prothoracicotropic hormone (PTTH) in the brain of cockroach Periplaneta americana, which 
influences eclosion, molting, and diapause. [49-50]   
AANAT-produced melatonin serves many roles in vivo, including anatomical and 
behavioral functions, as well as antioxidant protection.[51-56]  Melatonin is a potent scavenger of 
free radicals, and is more affective at reducing oxidative damage than the classic antioxidants 
glutathione, vitamin C, and vitamin E.[55]  Animal AANAT is localized in the mitochondria, 
while the serotonin N-acetyltransferase (SNAT) homologs found in higher plants and 
cyanobacteria are found in both the mitochondria and chloroplasts.  These organelles are the sites 
of metabolic respiration and photosynthesis, and thus constitute the main source of free radicals 
generated in the cell.  Having acquired the ability to synthesize melatonin, these organelles can 
better reduce oxidative damage from reactive oxygen species (ROS).  It is theorized that 
chloroplasts and mitochondria were originally transferred from a bacterial species through 
endosymbiosis with their eukaryotic host cells, and the highly-conserved functions for melatonin 
synthesis were retained over the course of evolution.[28] 
As previously mentioned, N-acetyltransferase was first studied in conjunction with 
sclerotization of the insect cuticle.[57]  NATs are responsible for producing N-acetylated biogenic 
amines (such as N-acetyldopamine) which are precursors used to couple chitin and arthopodin 
via monoamine quinones.  Other substrates for this sclerotization pathway include 
catecholamines and phenolamines such as octopamine, tyramine, tryptamine, and 
norepinephrine.  In vertebrates, these amines are metabolized by MOAs, but this pathway is 
absent from insects, where the monoamines are in high concentration during molting cycles.[58]  
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1.4 The Discovery and Characterization of iAANAT 
The pioneering identification and isolation of AANAT in vertebrates proved exceedingly 
difficult: this enzyme is highly light-sensitive, and detection required Bolton-Hunter labeling 
with a yield too small for sequence determination.[59]  In fact, differential cloning successfully 
identified AANAT before purification efforts were completed.[60-61]  However, iAANAT was 
much more photorefractory, and was successfully purified via HPLC.  The protein sequence was 
determined from cleavage products from cDNA cloned from the male gonad of P. americana.[62]  
Chromatographic isolation and characterization revealed at least two types of NATs occurred in 
different fractions, defined by pH optima and substrate specificity.  These two variants were 
designated NATa and NATb, with pH optima at acidic and basic ranges, respectively.  Different 
insect organs (CNS, midgut, and reproductive glands of both sexes) accommodate different 
ratios of the protein forms, while the two types exhibit varying affinities to serotonin, tryptamine, 
and octopamine.[63]  This was the first evidence that suggested AANAT activities consist of a 
family of enzymes. 
iAANAT activity in Drosophila melanogaster was first discovered in 1972,[58] followed 
soon after by its initial characterization in 1977.[64]  In 1995, the Hintermann group successfully 
purified the D. melanogaster AANAT,[45] which they later identified two biologically relevant 
isoforms, variant A (AANATA) and variant B (AANATB).[65]  The enzymes differ by a 35 
amino acid leader peptide on the N-terminus of variant B, however our group showed no 
enzymatic differences in binding or catalytic efficiency between the two forms.[17]  AANATA 
and AANATB are expressed in different tissues and at varying life stages, with AANATA 
located in the brain, midgut, and ventral nerve cord during late-stage embryogenesis and in adult 
flies.  AANATB is less abundant, and is only evident in the brain in late-stage pupae and adults.  
12 
 
Our group built upon this work and identified eight putative AANAT-like enzymes in D. 
melanogaster which are proposed to play vital roles in the biosynthesis of fatty acid amides, one 
of which catalyzes the formation of long-chain N-acylserotonins.[16, 18] 
Since there is little similarity in the amino acid sequence homology of AANATs, the 
ordinary PCR approach was unsuccessful in producing AANAT from the domesticated 
silkworm, Bombyx mori. However, by recognizing conserved functional domains, Tsugehara, et 
al, successfully amplified cDNA from the B. mori brain-subesophageal ganglion (SOG).[44]  The 
cDNA encodes a 261 amino acid protein with a wide range of substrate affinities, including 
serotonin, dopamine, tryptamine, norepinephrine, and octopamine.  The transcript was found in a 
multitude of different tissues (head, ovary, testes, and flight muscles) over several developmental 
stages: eggs, larvae, and adults.  Recent work by the Zhu group identified a second novel B. mori 
AANAT (which they termed Bm-iAANAT2) that when knocked down, lead to a change in 
dopamine levels which can affect melanism.[66]  Our group has discovered a third, previously 
uncharacterized B. mori AANAT (Bm-iAANAT3), which will be the focus of the work in 
Chapter 2. 
 
1.5  The Role of iAANAT in Insect Circadian Rhythms and Photoperiodism 
Amherd and Hintermann demonstrated that melatonin rhythms had bimodal peaks in D. 
melanogaster; however, both AANAT enzymes failed to display circadian fluctuations in 
transcript concentrations.[45, 65, 67]  Interestingly enough, the opposite was true for Antheraea 
pernyi (Chinese oak moth), B. mori, and P. americana: AANAT showed a circadian rhythm in 
activity and in transcription.[41, 50, 63, 68]  It was concluded that the circadian system controls both 
AANAT transcription and expression; this in turn results in circadian fluctuations between 
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serotonin and melatonin, both daily and seasonally.  An expressed serotonin receptor in the 
PTTH neuron then blocks the release of prothoracicotropic hormone, and induces and maintains 
diapause.[28]  Seasonal changes in day-length affect AANAT activity: it is up –regulated by long 
day conditions and down-regulated on shorter days.  Therefore, iaanat acts as a clock-controlled 
gene (CCG), where photoperiodism depends on a dual-control mechanism of diapause induction 
and maintenance versus diapause termination.[68] 
This was a striking discovery because iAANAT does not display timezyme functions, 
despite the findings that it is the critical point between the circadian system and photoperiodism 
in A. pernyi.[68]  iAANAT shares several similarities to vtAANAT in the endocrine switch, as 
supported by the following evidence. (1) iaanat is highly controlled by a negative feedback loop 
via several E-box elements: four canonical E-boxes (CANNTG) and two perfect E-boxes 
(CACGTG), all found in the iaanat promoter region.[28]  As mentioned previously, qRT-PCR 
exhibited rhythmical expression of iaanat in the light-dark cycle.  RNAi knockdown of per (a 
putative negative regulator of E-box) resulted in an up-regulation of aanat transcription.  In 
contradiction, RNAi used against Clk and cyc, positive regulators of E-box, suppressed the 
expression levels of aanat.  These results are similar to findings in chickens, where the 
abundance of vtAANAT mRNA exhibits circadian rhythms in the pineal gland, which is 
controlled by BMAL1/MOP4 and BMAL1/CLOCK heterodimers via E-box regulation.[26, 69] (2) 
iAANAT contributes to insect photoperiodism.  When pupae were injected with dsRNAiAANAT, 
they failed to emerge, even under long day conditions.  Pupae injected with dsRNAper showed a 
higher proportion of emergence, including under short day settings.  In mammals, nocturnally-
secreted melatonin provides an endocrine signal of photoperiod to the pars tuberalis (the anterior 
lobe of the pituitary gland); this, in turn, regulates a thyroid-stimulating hormone which 
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modulates seasonal reproduction.[70] (3) Melatonin concentration is regulated by the expression 
level of iaanat.  Melatonin levels were significantly higher than control subjects after the 
knockdown of per after 24 hours, however the injection of dsRNAiAANAT into pupae induced a 
large decline of melatonin over 48 hours. In vertebrates, pineal melatonin concentration is 
influenced by the changes in activity and expression levels of vtAANAT, which increases 10- to 
100-fold at night.[39]  Finally, (4) iAANAT is located within unique neuroendocrine cells which 
control photoperiodism.  iAANAT-like immunoreactivity was observed in a pair of co-localized 
putative “clock neurons,” which is reflective of vtAANAT expression in the pineal gland, 
proximal to the pars tuberalis.[70]    
As previously noted, AANAT activity exhibits a nocturnal increase which produces 
dramatically more melatonin during night hours.  An elegant study conducted in 1972 by 
Deguchi and Axelrod first measured the activity of AANAT via a radioenzymatic assay utilizing 
[14C]-acetyl CoA.  This highly sensitive analysis detected a 50-fold increase of AANAT activity 
in the rat pineal gland at night.[71]  Another study performed by Korf in 1994 discovered that 
AANAT activity (and the consequent melatonin secretions) is abolished by light signals received 
in photoreceptors dictated by peripheral oscillators.[72]  In mammals, photoreception occurs first 
in the retina, which induces endogenous oscillation in the SCN, and then finally produces 
melatonin secretions in the pineal gland.  However, the action of phototransduction for AANAT 
regulation in invertebrates remains unclear.  Recent findings regarding spectral responses have 
illustrated that visual pigments may mediate light-induced suppression of AANAT activity in 
these organisms, analogous to melanopsin in vertebrates.[73]  In C. elegans and the band-legged 
cricket D. nigrofasciatus, blue light is the most effective in suppressing AANAT activity (at 
wavelengths of 500 nm and 450 nm, respectively), [74-75]  while the mite T. urticae exhibits two 
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wavelengths of enzyme activity suppression (UV-A at 350 nm and blue light at 450 nm).  These 
spectral characteristics imply that certain short-wave photopigments may serve as the input 
system for phototransduction in regards to AANAT regulation in invertebrates.[28] 
 
1.6 Outline of the Research and Experimentation Detailed in this Dissertation 
The following chapters of this dissertation will pertain to the work conducted on a set of 
several enzymes produced and studied in the Merkler lab, three of which are completely novel.  
Chapter 2 expounds on our work with iAANAT from B. mori, where we demonstrate that Bm-
iAANAT is capable of catalyzing the condensation of long-chain acyl-CoA substrates with 
various biogenic amines.  We also delineate the full catalytic mechanism of Bm-iAANAT-3, a 
previously unstudied enzyme from this model organism.  This data, as well as ongoing efforts to 
acquire crystal structures of these AANAT enzymes, segues into our expertise in synthesizing 
activity-based protein profiling (ABPP) probes for the selective enrichment of enzymes from 
various organs, tissues, and/or entire cell lysates.  In Chapter 3, we detail the development and 
utilization of a probe used to enrich proteins that bind adenine and adenosine nucleotides, 
collectively known as AdoRs.  This research has far-reaching implications in cancer-based 
proteomics, and we hope further studies will eventually help to elucidate novel NAT enzymes 
from mammals using similarly devised probes.  Finally, Chapter 4 presents our work on DXS, 
the first and rate-limiting enzyme of isoprenoid biosynthesis in the malaria-causing protists 
Plasmodium falciparum and Plasmodium vivax.  By studying the mechanism of binding for these 
enzymes, we hope to contribute to ongoing efforts to develop novel antimalarial compounds. 
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CHAPTER TWO: 
A PAIR OF ARYLALKYLAMINE N-ACYLTRANSFERASES FROM BOMBYX MORI: 
PREVIOUSLY UNIDENTIFIED LONG-CHAIN N-ACYLARYLALKYLAMINE 
BIOSYNTHESIS & THE FULL MECHANISTIC ANALYSIS OF A NOVEL INSECT 
AANAT ENZYME 
 
2.1 An Introduction to Bombyx mori iAANAT 
Arylalkylamine N-acyltransferase (AANAT) catalyzes the N-acylation of arylalkylamines 
with acyl-CoA substrates, and has been intensely studied in mammals where it has earned the 
moniker “timezyme” due to its role in diurnal melatonin production.[1-6]  In this pathway, 
AANAT serves as the penultimate and rate-limiting enzyme responsible for acetylating serotonin 
to form N-acetylserotonin (NAS).  NAS is then methylated by hydroxyindole-O-
methyltransferase (HIOMT) to melatonin.  However, for all we know about the role of this 
enzyme in vertebrates, much less is known about AANAT in insects (iAANAT), where it has 
been implicated in a wide variety of biophysical functions. iAANAT performs vital reactions in 
the inactivation of monoamine neurotransmitters, sclerotization of the insect cuticle, suppression 
of melanism, production of melatonin, and is involved in seasonal photoperiodism and 
developmental events such as eclosion, molting, spinning activity, and diapause.[7-11] 
To date, a pair of recombinant AANAT enzymes have been cloned and characterized 
from the domesticated silkworm, Bombyx mori, an important economic insect and molecular 
model.  Tsugehara, et al. first studied Bm-iAANAT in 2007, where its mRNA expression was 
found in eggs, larvae, adult flies and various tissues.[12]  This result hinted that Bm-iAANAT may 
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be involved in the general metabolism of monoamines in various tissues, in contrast to 
vertebrates where AANATs are found primarily in the pineal gland and retina.  The identity and 
similarity between the deduced amino acid sequences of DmA-iAANAT1 (from D. 
melanogaster) and  Bm-iAANAT were 27.8% and 49.8%, respectively, while the identity and 
similarity of Bm-iAANAT with sheep AANAT were lower at 20.9% and 32.6%, respectively.  
Analysis with the Pfam database confirmed that  Bm-iAANAT contained an acetyltransferase 
domain of the GCN5-related N-acetyltransferase (GNAT) superfamily, consistent with studies 
pertaining to other N-acyltransferase enzymes.[13]  They also conducted various kinetic analyses, 
and detected AANAT activity when serotonin, octopamine, dopamine, norepinephrine, 
tryptamine, or tyramine was used as a substrate with acetyl-CoA.  Since AANAT activity and 
melatonin are both detected in the silkworm head,[7] and Bm-iAANAT acetylated serotonin and 
the mRNA transcript was also expressed in this region, the group reasoned this enzyme may be 
related to melatonin production in the head of B. mori.   
Diverse substrate specificity, in addition to broad tissue distribution, suggests that Bm-
iAANAT may be implicated in sclerotization of the insect cuticle (N-acetyldopamine and N-
acetylnorepinephrine are precursors used to couple chitin and arthopodin via monoamine 
quinines) and could be a major enzyme in the catabolism of monoamines.  The biosynthesis and 
degradation of these important neurotransmitters must be maintained at appropriate cellular 
levels, and dysfunction in either of these opposing pathways would lead to errors in the processes 
regulated by them.[14]  Dai et al. also studied Bm-iAANAT and its role in melanism.[9]  In 
Bombyx mori, roughly 100 gene mutation systems are associated with aberrant color patterns.  
One such mutation is the melanism (mln) mutant, a rare body coloration abnormality that leads to 
darker pigmentation.  A family of AANAT enzymes converts dopamine to N-acetyldopamine, a 
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precursor to the colorless N-acetyldopamine sclerotin; however, the dysfunction of AANAT 
expression may be related to melanism in insects.  The group concluded that the candidate gene 
of the mln locus was bm-iaanat, and found that dopamine content was twice as high in sclerified 
tissues compared to wild type.  They proposed that the higher concentration of dopamine was a 
direct result of the functional deficiency of bm-iaanat in the mutant, causing darker coloration in 
sclerified regions.[9] 
Long et al. have recently discovered and characterized a second AANAT enzyme from B. 
mori, Bm-iAANAT2. [15]  This protein shares 57% amino acid identity with Bm-iAANAT and 
was strongly expressed in the head, midgut, fat body, integument tubules, sex organs, and 
hemocyte.  The group constructed transgenic flies where Bm-iAANAT2 expression was 
suppressed, and subsequently identified increased melanin deposition in the head and 
integument.  Dopamine levels were elevated in the head, thus confirming a reduction in AANAT 
activity lead to changes in melanism patterns.  They also cloned and expressed recombinant Bm-
iAANAT2, and found it acetylated tryptamine to form N-acetyltryptamine, displaying weak in 
vivo activity.   
In addition to its role in the inactivation of primary amines through N-acetylation, it was 
postulated that AANATs may exist that catalyze the direct conjugation of long-chain acyl-CoAs 
to various biogenic amines to form the N-acylarylalkylamides.  This class of fatty acid amide is 
an emerging class of cell signaling lipids, and their biosynthetic routes in vivo are largely 
unidentified (with the exception of N-arachidonoylethanolamine, or anandamide, which has been 
extensively studied).  Recent work by Dempsey et al. elucidated the first AANAT that catalyzed 
the formation of long-chain N-acylserotonins and N-acyldopamines in D. melanogaster, 
compounds suggested to act as potent neurotransmitters.[16]  This enzyme, termed Dm-
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AANATL2, displayed chemistry consistent with reactions catalyzed by similar arylalkylamine 
N-acetyltransferases and other proteins of the GCN5-related N-acetyltransferase (GNAT) family 
of enzymes. 
In this chapter, we outline our work with Bm-iAANAT, as well as a novel AANAT from 
Bombyx mori.  We reasoned that previous kinetic analyses of Bm-iAANAT were limited in their 
extent of substrate screening; therefore, this formerly characterized enzyme was extensively 
assayed with assorted long-chain acyl-CoA substrates.  We found that this enzyme does indeed 
catalyze the conjugation reaction of several amines with various long-chain CoAs of different 
lengths, a previously overlooked aspect of Bm-iAANAT catalysis.   
Furthermore, we cloned and characterized a novel AANAT enzyme from B. mori, which 
we have designated Bm-iAANAT3.  This enzyme displays broad specificity with short-chain 
acyl-CoAs exclusively, with catalytic rates roughly 600x greater than Bm-iAANAT (when 
catalyzing the N-acetylation of tryptamine with acetyl-CoA).  We conducted several analyses to 
solve the kinetic mechanism, including double-reciprocal analysis, dead-end inhibition, pH-
activity profiling, and site-directed mutagenesis experiments to elucidate the first proposed 
chemical mechanism of an AANAT from Bombyx mori. 
 
2.2 Experimental Procedures 
2.2.1 Materials and General Methods 
Unless otherwise noted, all reagents were obtained from commercial sources. Codon-
optimized Bm-iAANAT and Bm-iAANAT3 were purchased from Genscript. Oligonucleotides 
were purchased from Eurofins MWG Operon. BL21 (DE3) E. coli cells, XL-10 competent cells, 
and the pET-28a(+) vector were purchased from Novagen.  PfuUltra High-Fidelity DNA 
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polymerase was purchased from Agilent.  XhoI, NdeI, Antarctic Phosphatase, and T4 DNA 
ligase were purchased from New England Biolabs. Kanamycin monosulfate and IPTG were 
purchased from Gold Biotechnology.  ProBond nickel-chelating resin was purchased from 
Invitrogen. Long and short-chain acyl-CoAs and amine substrates were purchased from Sigma-
Aldrich.  All other supplies and materials were of the highest quality available from either Sigma 
or Fisher Scientific. Spectrophotometric analyses were performed on a Cary 300 Bio UV-Visible 
spectrophotometer.   
2.2.2 Molecular Cloning of Bm-iAANAT and Bm-iAANAT3 
Bm-iAANAT (Accession No. NM_001079654.2)  and Bm-iAANAT3 (Accession No. 
NM_001190842.1)   were codon optimized for expression in E. coli, with 5’-NdeI and 3’-XhoI 
restriction sites, and synthesized into a pUC57 vector.  The full-length gene was excised from the 
pUC57 vector and cloned into the NdeI and XhoI restriction sites of the pET-28a vector.  The 
Bm-iAANAT-pET28a and Bm-iAANAT3-pET28a vectors were then transformed into E. coli XL-
10 competent cells, plated on a Luria Broth (LB) agar plate supplemented with 50 μg/mL 
kanamycin, and grown overnight at 37°C.  A single colony from each vector transformation was 
cultured overnight in LB media supplemented with 50 μg/mL kanamycin overnight at 37°C.  The 
Bm-iAANAT-pET28a and Bm-iAANAT3-pET28a plasmids were purified from the overnight 
cultures using the Promega Wizard Plus SV Minipreps DNA purification kit, sequenced by 
Eurofins MWG Operon to confirm correct gene insertion, and finally transformed into E. coli 
BL-21 (DE3) cells for the expression of either Bm-iAANAT or Bm-iAANAT3. 
2.2.3 Protein Expression and Purification 
The E. coli BL-21 (DE3) competent cells containing either the Bm-iAANAT-pET28a or 
Bm-iAANAT3-pET28a vector were cultured in LB media supplemented with 50 μg/mL 
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kanamycin at 37°C.  Once the cultures reached an OD600 of 0.6, cells were induced with the 
addition of 1.0 mM isopropyl β-D-thiogalactopyranoside (IPTG) for 4 hours at 37°C.  The final 
cultures were harvested by centrifugation at 6,000g for 10 minutes at 4°C, and pellets were 
frozen at -80°C for later analysis. 
Cell pellets were thawed and resuspended in Binding buffer: 20 mM Tris pH 7.9, 500 
mM NaCl, and 5 mM imidazole.  Cells were lysed by sonication and the cellular debris was 
pelleted by centrifugation at 16,000g for 20 minutes at 4°C.  The supernatant was retained and 
loaded onto a 5 mL of ProBond nickel-chelating resin.  The column was washed with 5 column 
volumes (CVs) of Binding buffer, followed by 10 CVs of Wash buffer: 20 mM Tris pH 7.9, 500 
mM NaCl, and 60 mM imidazole.  Finally, purified enzyme was eluted from the column in 1 mL 
fractions with 2-3 CVs of Elution buffer: 20 mM Tris pH 7.9, 500 mM NaCl, and 500 mM 
imidazole.  Fractions were evaluated for purity and protein concentration using 10% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels and Bradford binding 
assay, respectively.  Fractions containing purified AANAT enzyme were pooled, dialyzed 
overnight in 20 mM Tris pH 7.4, 200 mM NaCl, and stored at -80°C. 
2.2.4 Enzyme Screening Assay 
Each Bombyx mori AANAT was subjected to an activity-based screening to elucidate 
relevant substrates.  First, each enzyme was evaluated using acetyl-CoA (representative of short-
chain CoAs) or oleoyl-CoA (exemplary of long-chain CoA catalysis) separately, with different 
groups of pooled amines.  The groups of amines are listed in Table 2.1.  The assay conditions 
consisted of 300 mM Tris pH 8.0, 150 μM DTNB (5,5’-dithiobis(2-nitro-benzoic acid) or 
Ellman’s reagent), 500 μM of either coenzyme A substrate, and 60 mM of each of the amine 
pools at 22°C.  Initial velocities were determined by measuring the release of CoA at 412 nm 
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(molar extinction of Ellman’s reagent = 13,600 M-1 cm-1), with the reported velocities calculated 
as the background hydrolysis rate subtracted from the observed velocity. 
Table 2.1 Pooled amine substrates for the initial screening assay 
 
 
 
 
 
  
Any CoA and amine group combination that displayed a background-corrected rate ≥ 0.1 
μmoles/min/mg was considered a “significant velocity.”  The corresponding amines were then 
individually interrogated further at saturating conditions with the respective CoA to deduce 
which were true substrates for AANAT.  The assay conditions were identical as the pooled 
screening step, and individual amines that displayed a rate of ≥ 0.1 μmoles/min/mg above 
background were then assayed to determine steady-state kinetic constants (see section 2.2.5).  
2.2.5 Activity Assay for Determining Steady-State Kinetic Constants 
Steady-state kinetic characterization for both Bm-iAANAT and Bm-iAANAT3 were 
assayed using Ellman’s reagent by measuring the release of coenzyme A at 412 nm under the 
following conditions: 300 mM Tris pH 8.0, 150 μM DTNB, and varying concentrations of 
substrates at 22°C.  To test kinetic constants for Bm-iAANAT, the initial tryptamine 
concentration was held at 60 mM while the long-chain acyl-CoA substrates were varied.  To 
assay the kinetic constants for the amines, tryptamine, tyramine, octopamine, and serotonin were 
varied while oleoyl-CoA was held at 100 μM.  For assaying the kinetic constants of Bm-
Group Amino Donors 
1 Lysine, Threonine, Glycine, Histamine,  Dopamine  
2 Alanine, Arginine, Histidine, Tyramine, Norepinephrine  
3 Serine, Proline, Methionine, Serotonin, Tryptamine  
4 Glutamate, Asparagine, Valine, Ethanolamine, Octopamine  
5 Aspartate, Isoleucine, Tryptophan, Glutamine  
6 Leucine, Phenylalanine, γ-Aminobutyric acid, Taurine  
7 Spermidine, Agmatine, Cadaverine, Putrescine, B-Alanine  
8 
Kanamycin, Neomycin A, Tobraymcin 
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iAANAT3, tryptamine was held constant at 8 mM while the short-chain acyl-CoA substrates 
were varied.  Alternatively, the significant amino donors were assayed while acetyl-CoA was 
held at 500 μM.  The apparent kinetic constants were determined by fitting the resulting data to 
Equation 2.1 using SigmaPlot 12.0: vo represents initial velocity, Vmax,app is the apparent maximal 
velocity, Km,app is the apparent Michaelis constant, and [S] is the substrate concentration.  Assays 
were performed in triplicate and the uncertainty for the kcat,app and (kcat/Km)app values were 
calculated using Equation 2.2, where σ is the standard error.[17] 
 
Equation 2.1 
vo =  
Vmax,app[S]
Km,app + [S]
 
 
Equation 2.2 
σ (
x
y
) =
x
y
√(
σx
x
)
2
+ (
σy
y
)
2
 
 
2.2.6 Bm-iAANAT Product Characterization  
To confirm the product formation of Bm-iAANAT, 1 mM tryptamine and 500 μM of 
oleoyl-CoA were incubated with 100 μg of the enzyme for 1 hour in 300 mM Tris pH 8.0 (this 
ratio of substrates was deemed ideal after several optimization studies, since Bm-iAANAT is 
easily inhibited by an excess of amine donor).[12]  The reaction mixture was then passed through 
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a 10 kDa ultrafilter (Millipore) to remove the enzyme.  No enzyme blanks were also prepared. 20 
μL of the resulting flow-through solution containing the oleoyl-tryptamine conjugation product 
was injected on an Agilent 6540 liquid chromatography/quadrupole time-of-flight mass 
spectrometer (LC/QTOF-MS) in positive ion mode.  Product separation was completed on a 
Kinetex 2.6 μm C18 100 Å (50 x 2.1 mm) reverse phase column with the following mobile phase 
gradient: mobile phase A consisted of water with 0.1% formic acid, while mobile phase B was 
comprised of acetonitrile with 0.1% formic acid.  A linear gradient of 10% mobile phase B 
increased to 100% B over 5 minutes, followed by a hold-up of 3 minutes at 100% B for the 
liquid chromatography analysis of the product.  The column was then equilibrated with 10% 
mobile phase B for 10 minutes before subsequent injections.  
2.2.7 Kinetic Mechanism Elucidation of Bm-iAANAT3 
2.2.7.1 Double Reciprocal Analysis 
To delineate between a sequential and classic ping-pong mechanism, double-reciprocal 
plots of the initial velocity data were generated for acetyl-CoA and tryptamine in SigmaPlot 
12.0.  Non-linear regression analysis of initial rates and model discrimination analyses were 
performed in WaveMetrics IGOR Pro 6.34A.  Initial velocities were determined by varying the 
concentration of one substrate, while holding the other substrate at a fixed concentration.  The 
two plots were generated by holding the tryptamine concentration constant (50 μM, 100 μM, 250 
μM, and 500 μM) and varying the concentration of acetyl-CoA.  Accordingly, the second plot 
held the concentration of acetyl-CoA constant (45 μM, 90 μM, 225 μM and 450 μM) and varied 
the tryptamine concentration.  The resulting initial velocity data was fit to Equation 2.3 for an 
ordered Bi-Bi mechanism, where vo is the initial velocity, Vmax is the maximal velocity, [A] is 
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the concentration of substrate A, [B] is the concentration of substrate B, Kia is the dissociation 
constant for substrate A, Kb is the Michaelis constant for substrate B, and Ka is the Michaelis 
constant for substrate A. 
 
Equation 2.3 
vo =
Vmax[A][B]
KiaKb + Ka[B] + Kb[A] + [A][B]
 
 
2.2.7.2 Dead-end Inhibition with Oleoyl-CoA and Tyrosol 
To further explicate the kinetic mechanism of Bm-iAANAT3, we used dead-end 
inhibition analysis using oleoyl-CoA and tyrosol.  The initial velocities were generated by 
holding one substrate (either acetyl-CoA or tryptamine) at a fixed concentration, varying the 
concentration of the other substrate, at different fixed concentrations of each inhibitor.  All 
assays were performed in triplicate, and the resulting data was fit to Equations 2.4 – 2.6 in 
SigmaPlot 12.0 for competitive, noncompetitive, and uncompetitive inhibition, respectively.  For 
Equations 2.4 – 2.6, vo is the initial velocity, Vmax,app is the apparent maximal velocity, Km,app is 
the apparent Michaelis constant, [S] is the substrate concentration, [I] is the inhibitor 
concentration, and Ki is the inhibition constant. 
Equation 2.4 
vo =
Vmax,app[S]
Km,app (1 +
[I]
Ki
) + [S]
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Equation 2.5 
vo =
Vmax,app[S]
Km,app (1 +
[I]
Ki
) + [S] (1 +
[I]
Ki
)
 
 
Equation 2.6 
vo =
Vmax,app[S]
Km,app + [S] (1 +
[I]
Ki
)
 
 
2.2.7.3 Bm-iAANAT3 Rate versus pH Dependence  
The pH dependence on the apparent kinetic constants was determined for both tryptamine 
and acetyl-CoA, at intervals of 0.5 pH units ranging from pH 6.5 to 9.5.  The buffers used 
consisted of the following: MES (pH 6.5), Tris (pH 7.0 – 9.0) and AmeP (pH 9.0 – 9.5).  The 
resulting kinetic data were fit to Equations 2.7 and 2.8 in WaveMetrics IGOR Pro 6.34A to 
delineate the apparent pKa values of measured ionizable groups.  In both equations, c is the pH-
independent plateau. 
 
Equation 2.7 
log(kcat/Km)app = log[c/(1 + 10
pKa−pH)] 
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Equation 2.8 
log kcat,app = log[c/(1 + 10
pKa−pH)] 
 
2.2.7.4 Generation of Site-directed Mutants  
To further investigate the role of amino acid residues possibly implicated in binding and 
catalysis, a pair of Bm-iAANAT3 mutants was produced: E27A and S167A.  The generation of 
both mutants was facilitated through the overlap extension method.[18]  Mutants were amplified 
with the PfuUltra High-Fidelity DNA polymerase with the following PCR conditions: an initial 
denaturation step of 95°C for 2 minutes, followed by 30 cycles of PCR amplification (95°C for 
30 s, 58°C for 30 s, 72°C for 1 min), and a final extension step of 72°C for 10 minutes.  Primers 
were designed on the Agilent QuickChange Primer Design tool (Table 2.2) and purchased from 
Eurofins MWG Operon.  PCR products were digested with NdeI and XhoI restriction enzymes 
and ligated into the pET28a vector with DNA ligase acquired from New England Biolabs.  
Mutant enzymes were expressed and purified in the same manner as the wild type Bm-iAANAT3 
(see section 2.2.3). 
Table 2.2 Bm-iAANAT3 site-directed mutagenesis primers 
 
 
 
 
Clone Primer Sequence 
Full Gene 
Forward GTAGCATATGGCTGATTTTGTTGTTGT 
Reverse GTAGCTCGAGTTACGGCAGTTTCAG 
E27A 
Antisense TCCTTCTTTGCCGATGCACCGCTGAACAAAGCC 
Sense GGCTTTGTTCAGCGGTGCATCGGCAAAGAAGGA 
S167A 
Antisense GGCAGATACGTTGAGCAAAGGCGCCGGTC 
Sense ACCGGCGCCTTTGCTCAACGTATCTGCC 
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2.3 Experimental Results 
2.3.1 Cloning, Expression, and Purification of Bm-iAANAT Enzymes 
Both Bm-iAANAT and Bm-iAANAT3 from Bombyx mori were successfully cloned, 
expressed, and purified from codon-optimized genes to yield 17.4 mg and 10.9 mg of purified 
protein per liter of culture, respectively.  Purity was assessed to be ≥95% by a 10% SDS-PAGE 
gel (see Figure 2.1) and both protein bands are in good agreement with their predicted masses 
(29.6 kDa for Bm-iAANAT and 23.9 kDa for Bm-iAANAT3). 
 
 
 
 
 
 
 
 
 
Figure 2.1 SDS-PAGE analysis. (A) Bm-iAANAT and (B) Bm-iAANAT3. 
Bm-iAANAT3 is a previously uncharacterized enzyme, and shares 25.3%, 23.4%, and 
26.5% sequence identity with Bm-iAANAT, Bm-iAANAT2, and Dm-AANATA, respectively 
(Figure 2.2). It shares slightly less identity with the mammalian AANATs from human and 
sheep, at 20.8% and 16.8% identity, respectively.  This analysis further confirms that these and 
other AANATs share poor homology, even from organisms of the same phylum and class. 
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Figure 2.2 Homology overlays of several AANAT enzymes from B. mori and D. melanogaster. 
 
2.3.2 Pooled Screening for the Elucidation of Bombyx mori AANAT Substrates 
2.3.2.1 Bm-iAANAT Screening with Long-Chain Acyl-CoA Substrates 
Our lab has developed a screening method comprised of eight groups of various amine 
substrates (arylalkylamines, polyamines, aminoglycosides, ethanolamine, histamine, and the 
cognate amino acids) that can be tested with both short and long-chain acyl-CoA substrates.  The 
concentration of the amines in the screening assay were held at high concentrations since some 
GNAT enzymes have been reported with high Km,app values: mouse GLYAT has a Km,app of 6 
mM for glycine.[19]  Pools of acyl-CoA substrates were not constructed because of numerous 
accounts of long-chain acyl-CoAs acting as inhibitors;[20] therefore, we individually screened 
archetypal short and long-chain thioesters in the form of acetyl-CoA and oleoyl-CoA (which has 
been reported previously as a substrate for several GNAT enzymes).[21]  The benefits of this 
technique are clear: any pool that shows no catalytic activity can be entirely disregarded for 
individual kinetic assessment.  When this strategy was applied to Bm-iAANAT with acetyl-CoA, 
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significant velocities (a background-corrected rate ≥ 0.1 μmoles/min/mg) were achieved with 
five of the eight amine substrate groups, confirming the promiscuous nature of this enzyme (see 
Table 2.3).  In addition to the amino donors already identified by Tsugehara et al. (tryptamine, 
serotonin, octopamine, dopamine, norepinephrine, etc.), we ascertained several previously 
unknown Bm-iAANAT substrates: lysine, histamine, alanine, tyramine, ethanolamine, as well as 
several polyamines including spermidine, agmatine, cadaverine, and putrescine. However, 
because of limitations of using Ellman’s reagent at low substrate concentrations (below ~1 μM), 
our spectrophotometric assay was not sensitive enough to calculate kinetic constants for many of 
the amines.  Several of the potential substrates that were hits from our screening method 
(tryptamine, dopamine, serotonin, tyramine, etc) had (Km, acetyl-CoA)app values of approximately 1 
μM or lower; Tsugehara et al. used a more sensitive [14C] acetyl-CoA radiocarbon assay and 
derived  Km,app  values of 0.31 μM and 1.7 μM for acetyl-CoA and tryptamine, respectively.[12]   
 
Table 2.3 Pooled screening results for Bm-iAANAT and Bm-iAANAT3. 
 
 
 
 
 
aConstitutes a “significant velocity” (a background-corrected rate ≥ 0.1 μmoles/min/mg).  The 
assay conditions consisted of 300 mM Tris pH 8.0, 150 μM (DTNB), 500 μM of either 
coenzyme A substrate, and 60 mM of each of the amine pools at 22°C. 
 
Acyl-
CoA 
                                     Velocity (μmoles/min/mg) 
                                                     Group 
1 2 3 4 5 6 7 8 
Bm-iAANAT 
Acetyl 1.18a 1.32a 1.03a 1.22a 0.01 0.04 1.96a 0.01 
Oleoyl 0.02 0.88a 0.91a 0.59a 0.02 0.02 0.01 0.00 
Bm-iAANAT3 
Acetyl 47.5a 48.1a 51.2a 12.4a 0.04 0.07 0.09 0.04 
Oleoyl 0.01 0.02 0.01 0.03 0.02 0.01 0.04 0.01 
 
 
 42 
 
Nevertheless, the diverse set of amine donors that acted as substrates and the 
promiscuous nature of Bm-iAANAT was encouraging, for we hypothesized this enzyme may be 
capable of catalyzing the formation of the long-chain N-acylarylalkylamides.  When the pooling 
strategy was repeated with oleoyl-CoA, three of the eight groups yielded significant velocities.  
Individual interrogation of these groups provided four positive results with a long-chain acyl-
CoA thioester: tryptamine, tyramine, serotonin, and octopamine (see Table 2.4) 
Table 2.4 Individual amine substrate specificity for Bm-iAANAT with oleoyl-CoA. 
 
 
 
 
The four arylalkylamines that had “significant velocities” (background-corrected rates ≥ 0.1 
μmoles/min/mg) in the individual pooling assay when reacted with oleoyl-CoA. 
 
Tryptamine was the “best” substrate for conjugation with oleoyl-CoA, with a Km,app of 
7.0 ± 0.5 mM and a (kcat/Km)app of (1.0 ± 0.07) x 10
2 M-1s-1.  Tyramine and octopamine displayed 
significantly higher Km,app values of 84 ± 12 and 65 ± 16 mM, respectively.  Unfortunately, at 
high concentrations, the formation of oleoyl-serotonin produced a precipitate that made 
spectrophotometric analysis impossible.  Yet, qualitatively speaking, the release of CoA-SH was 
clearly evident with the DTNB assay, due to its intense yellow color.  More optimization is 
required to define kinetic constants for this substrate. 
 To elucidate steady-state kinetic constants for Bm-iAANAT, we first varied tryptamine 
concentration while holding the concentration of several acyl-CoAs constant at 100 μM (Table 
CoA 
(100 μM) 
Varied 
Amine 
Km, app 
(mM) 
kcat, app 
(s-1) 
(kcat/Km)app 
(M-1 s-1) 
Relative 
(kcat/Km)app 
Oleoyl-
CoA 
Tryptamine 7.0 ± 0.5 0.72 ± 0.01 (1.0 ± 0.07) x 102 22 
Tyramine 84 ± 12 2.7 ± 0.19 32 ± 5.3 6.8 
Octopamine 65 ± 16 0.31 ± 0.04 4.7 ± 1.2 1.0 
Serotonin Precipitation at High Concentration 
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2.5).  The (Km, tryptamine)app values are all comparable, ranging from 2.5 mM to 7.0 mM.  There is 
also an explicit trend in regards to the acyl-CoA chain length.  The (kcat/Km)tryptamine,app was 
highest when the thioester substrate was lauroryl-CoA ((3.1 ± 0.5) x 102 M-1s-1) and continued to 
decline as the acyl chain length was increased.  We then evaluated various acyl-CoA thioesters to 
ascertain whether or not chain length affected catalysis (Table 2.6).  When tryptamine was held 
constant at saturating conditions and the concentration of the CoA substrate was varied, we again 
observe the same pattern: higher (kcat/Km)acyl-CoA,app values with shorter acyl-chain lengths that 
decreased as the alkyl moiety was extended.  This suggests that the longer chain lengths of the 
acyl-CoA substrates may disrupt binding of the amine substrate, hindering catalysis.   Tsugehara 
et al. assessed Bm-iAANAT under similar conditions, and calculated (Km,acetyl-CoA)app and 
(kcat/Km)acetyl-CoA,app values of 0.31 μM and 3.8 x 105 M-1s-1, respectively.[12]  These data suggest 
that Bm-iAANAT is catalytically more efficient at using the longer chain acyl-CoA substrates 
(up to palmitoyl-CoA) than acetyl-CoA when tryptamine is the corresponding amine in catalysis.   
Table 2.5 Apparent steady-state kinetic constants of Bm-iAANAT when tryptamine was varied 
and the acyl-CoA substrates were held constant. 
 
 
 
 
aBackground rates of acyl-CoA hydrolysis were obtained at saturating CoA concentrations in the 
absence of tryptamine, and subtracted from the rates in the presence of tryptamine.  Background 
hydrolysis rates were ≤5% of the catalytic rates in the presence of tryptamine. 
 
Varied 
Amine 
CoA 
(100 μM)a 
Chain 
Length 
Km, app 
(mM) 
kcat, app 
(s-1) 
(kcat/Km)app 
(M-1 s-1) 
Relative 
(kcat/Km)app 
Tryptamine 
Lauroryl 12:0 5.9 ± 1.0 1.8 ± 0.07 (3.1 ± 0.5) x 102 3.1 
Myristoyl 14:0 2.5 ± 0.2 0.66 ± 0.01 (2.7 ± 0.3) x 102 2.7 
Palmitoyl 16:0 3.0 ± 0.4 0.51 ± 0.01 (1.7 ± 0.2) x 102 1.7 
Oleoyl 18:1 7.0 ± 0.5 0.72 ± 0.01 (1.0 ± 0.07) x 102 1.0 
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 Table 2.6 Apparent steady-state kinetic constants of Bm-iAANAT when tryptamine was at 
saturating conditions and the acyl-CoA substrates were varied. 
 
 
 
 
 
 
aBackground rates of acyl-CoA hydrolysis were obtained at each CoA concentration in the 
absence of tryptamine, and subtracted from the rates in the presence of tryptamine.  Background 
hydrolysis rates were ≤5% of the catalytic rates in the presence of tryptamine. 
 
These data highlight the first AANAT identified in Bombyx mori that will catalyze the 
formation of long-chain N-acylarylalkylamides. When we compare the steady-state kinetic 
constants with those of Dm-AANATL2 from D. melanogaster (the first enzyme identified that 
generates long-chain N-acylserotonins and N-acyldopamines), we observe nearly identical values 
for (kcat/Km)oleoyl-CoA,app and (kcat/Km)amine,app (see tables 2.7 and 2.8 for comparisons of steady-
state kinetic constants between these two enzymes).  Dempsey et al. previously highlighted the 
relatively low (kcat,amine)app and (kcat,acyl-CoA)app for Dm-AANATL2 which is also evident in Bm-
iAANAT.  Notwithstanding, these low values are unsurprising since it is postulated that the long-
chain N-acylarylalkylamides serve as potent cell signaling lipids, and the kcat,app values measured 
are conceivably sufficient to supply cellular needs. It is possible that Bm-iAANAT is the enzyme 
responsible for the generation of these long-chain N-acylarylalkylamides, while a more 
catalytically potent Bombyx mori AANAT produces the short-chain compounds.   
Amine  
 (60 mM) 
Varied 
CoAa 
Chain 
Length 
Km, app 
(μM) 
kcat, app 
(s-1) 
(kcat/Km)app 
(M-1 s-1) 
Relative 
(kcat/Km)app 
Tryptamine 
Lauroryl 12:0 0.97 ± 0.12 1.3 ± 0.01 (1.4 ± 0.2) x 106 6.2 
Myristoyl 14:0 0.92 ± 0.20 0.66 ± 0.01 (7.2 ± 1.5) x 105 3.2 
Palmitoyl 16:0 1.1 ± 0.30 0.51 ± 0.01 (4.9 ± 1.4) x 105 2.2 
Oleoyl 18:1 1.7 ± 0.51 0.42 ± 0.02 (2.4 ± 0.7) x 105 1.1 
Arachidoyl 20:4 1.2 ± 0.67 0.27 ± 0.02 (2.3 ± 1.3) x 105 1.0 
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Table 2.7 Comparisons of kinetic constants from Dm-AANATL2 versus Bm-iAANAT when the 
amine substrate was saturating. 
 
 
 
 
 
1 Dempsey, et al., Identification of an AANAT from D. melanogaster... FEBS Lett. 2014, 588 
(4), 594-599. 
2 Tsugehara, T et al., Cloning and characterization of iAANAT from B. mori. Comp. Biochem. 
Physiol. B-Biochem. Mol. Biol. 2007, 147 (3), 358-366. 
 
 
Table 2.8 Comparisons of kinetic constants from Dm-AANATL2 versus Bm-iAANAT when 
oleoyl-CoA was saturating. 
 
 
 
 
1 Dempsey, et al., Identification of an AANAT from D. melanogaster... FEBS Lett. 2014, 588 
(4), 594-599. 
 
 
2.3.2.2 Bm-iAANAT3 Screening with Short-Chain Acyl-CoA Substrates 
We again implemented our screening assay with the novel Bm-iAANAT3 enzyme, 
however failed to achieve any significant velocities with oleoyl-CoA, suggesting this enzyme 
does not catalyze the formation of long-chain N-acylamides.  However, when the thioester 
substrate was acetyl-CoA, we observed a broad range of specificity in regards to the amines, at 
Enzyme Varied CoA 
Saturating 
Amine 
Km, app 
(μM) 
kcat, app 
(s-1) 
(kcat/Km)app 
(M-1 s-1) 
Dm-
AANATL2 
Acetyl-CoA1 Serotonin 6.1 ± 0.3 1.3 ± 0.012 (2.2 ± 0.02) x 105 
Oleoyl-CoA1 Serotonin 3.6 ± 0.6 0.075 ± 0.003 (2.1 ± 0.09) x 104 
Bm-iAANAT 
Acetyl-CoA2 Tryptamine 0.31 0.11 3.8 x 105 
Oleoyl-CoA Tryptamine 1.7 ± 0.51 0.42 ± 0.02 (2.4 ± 0.7) x 105 
 
Enzyme 
Saturating 
CoA 
Varied 
Substrate 
Km, app 
(mM) 
kcat, app 
(s-1) 
(kcat/Km)app 
(M-1 s-1) 
Dm-AANATL2 
Oleoyl-CoA1 Serotonin 0.5 ± 0.1 0.085 ± 0.006 (1.7 ± 0.12) x 102 
Oleoyl-CoA1 Dopamine 1.2 ± 0.2 0.058 ± 0.003 (4.7 ± 2.7) x 102 
Bm-iAANAT Oleoyl-CoA Tryptamine 7.0 ± 0.5 0.72 ± 0.01 (1.0 ± 0.07) x 102 
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rates nearly ~50x higher than that of Bm-iAANAT (see Table 2.3).  When we further 
investigated the individual amines from the four pools that were categorized as hits, we 
elucidated six arylalkylamides and histamine that underwent catalysis.  The order of substrates 
ranked in decreasing rates of catalysis is as follows: tryptamine, tyramine, dopamine, 
octopamine, serotonin, norepinephrine, and histamine (Table 2.9). 
 
Table 2.9 Apparent steady-state kinetic constants of Bm-iAANAT3 when acetyl-CoA was held 
constant at 500 µM and the amine substrate concentration was varied. 
 
 
 
 
 
 
 
Tryptamine catalysis was ~30x more potent than histamine, the least catalytic substrate.  
Octopamine displayed the lowest Km,app value of 18 ± 0.77 µM, while histamine displayed the 
highest Km,app of 1.7 ± 0.1 mM.  One noticeable characteristic of all of these substrates is that 
they each possess a two methylene spacer between the amino group and the aromatic moiety.  
None of the polyamines, aminoglycosides, or amino acids served as substrates for Bm-
iAANAT3.  This suggests that positioning of the primary amine in an optimal configuration for 
nucleophilic attack is critical for catalysis. 
Amine 
Km, app 
(μM) 
kcat, app 
(s-1) 
(kcat/Km)app 
(M-1 s-1) 
Relative (kcat/Km)app 
Tryptamine 97 ± 8.8 60 ± 1.2 (6.2 ± 0.6) x 105 33 
Tyramine 63 ± 6.7 27 ± 0.64 (4.3 ± 0.5) x 105 23 
Dopamine 330 ± 23 55 ± 1.1 (1.6 ± 0.1) x 105 8.4 
Octopamine 18 ± 0.77 2.2 ± 0.02 (1.2 ± 0.05) x 105 6.3 
Serotonin 1100 ± 63 59 ± 1.0 (5.2 ± 0.3) x 104 2.7 
Norepinephrine 140 ± 8.6 5.3 ± 0.07 (3.7 ± 0.2) x 104 1.9 
Histamine 1700 ± 98 33 ± 0.68 (1.9 ± 0.1) x 104 1.0 
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Interestingly, acetyl-CoA displayed the highest Km,app value of the assayed short-chain 
CoA substrates at 90 ± 3.6 µM.  The other four CoAs exhibited nearly identical Km,app values of 
10 to 14 µM (Table 2.10).  As was the case with Bm-iAANAT, catalysis decreased with 
increased acyl CoA chain length: acetyl-CoA exhibited a (kcat/Km)acyl-CoA,app 170x greater than 
decanoyl-CoA, the longest coenzyme A substrate that demonstrated appreciable enzymatic rates. 
 
Table 2.10 Apparent steady-state kinetic constants of Bm-iAANAT3 when tryptamine was held 
constant at 8 mM and the acyl-CoA substrate concentration was varied. 
 
 
 
 
 
2.3.3 Product Characterization of the Bm-iAANAT-Catalyzed Reaction 
After discovering that Bm-iAANAT catalyzed the formation of long-chain N-
acylarylalkylamides via our substrate screening assay, we set out to confirm the predicted N-
acylamide product from an in vitro reaction mixture by high resolution mass spectrometry.  We 
assayed a synthesized N-oleoyltryptamine standard against the N-acylamide product of the 
reaction mixture described in section 2.2.6, and compared the retention times and m/z values of 
the [M+H]+ peak using LC/QTOF-MS.  The findings corroborated our kinetic data: the N-
oleoyltryptamine produced from the Bm-iAANAT-catalyzed reaction is consistent for the 
[M+H]+ peak and retention time (± 0.1 reported error for the LC/QTOF-MS) versus our 
Acyl-CoA 
Chain 
Length 
Km, app 
(μM) 
kcat, app 
(s-1) 
(kcat/Km)app 
(M-1 s-1) 
Relative 
(kcat/Km)app 
Acetyl 2:0 90 ± 3.6 64 ± 0.74 (7.1 ± 0.3) x 105 170 
Butyrl 4:0 14 ± 0.75 4.0 ± 0.04 (2.9 ± 0.2) x 105 70 
Hexanoyl 6:0 13 ± 0.54 1.3 ± 0.01 (9.5 ± 0.4) x 104 23 
Octanoyl 8:0 10 ± 1.0 0.36 ± 0.005 (3.4 ± 0.3) x 104 8.1 
Decanoyl 10:0 12 ± 5.5 0.05 ± 0.004 (4.2 ± 1.9) x 103 1.0 
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synthesized standard N-oleoyltryptamine (Table 2.11).  We did not detect N-oleoyltryptamine in 
the no enzyme-containing (blank) samples.  Further work will be conducted to confirm the 
formation of the other previously identified long-chain N-acylarylalkylamides with this 
technique. 
 
Table 2.11 Product characterization of the Bm-iAANAT-catalyzed reaction via LC/QTOF-MS 
analysis. 
 
 
 
 
 
2.3.4 Kinetic Mechanism of Bm-iAANAT3  
We utilized several different enzymatic experiments to deduce the kinetic mechanism of 
Bm-iAANAT3.  First we constructed double reciprocal plots of initial velocities of acetyl-CoA 
and tryptamine, while holding the other substrate at a fixed concentration.  The resulting plots 
(Figure 2.3) display intersecting lines for both substrates, indicative of a sequential mechanism 
where both tryptamine and acetyl-CoA must be bound to the enzyme to form a ternary complex.  
Only then can catalysis proceed.  This is in contrast to the classical ping-pong mechanism, where 
the first substrate binds and releases the first product (forming a metastable intermediate) before 
binding of the second substrate occurs. The initial velocities were also subjected to global non-
linear regression analysis, in which several mechanistic models for a Bi-Bi system were 
examined in a model discrimination analysis.  The model discrimination also best supported a 
steady-state ordered mechanism.   
Sample Retention Time (min) [M+H]+ (m/z) 
N-oleoyltryptamine Standard 6.489 425.2588 
Bm-iAANAT product 6.503 425.2574 
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Figure 2.3 Bm-iAANAT3 double-reciprocal analysis of initial velocities for acetyl-CoA and 
tryptamine, fit to equation 2.3 in a global non-linear regression analysis.  (A) Velocities 
measured at fixed concentrations of tryptamine: 500 µM (), 250 µM (), 100 µM (), and 50 
µM ().  (B) Velocities measured at fixed concentrations of acetyl-CoA: 450 µM (), 225 µM 
(), 90 µM (), and 45 µM (). 
 
 
To distinguish between an ordered or random sequential mechanism, we employed 
inhibition studies.  Oleoyl-CoA and tyrosol were exploited as dead-end inhibitors against acetyl-
CoA and tryptamine, respectively.  Neither analog exhibited a rate of reaction above the baseline 
rate of hydrolysis, and both have been previously utilized as dead-end inhibitors for the kinetic 
mechanism determinations of D. melanogaster AANATs[14, 22] and mammalian serotonin N-
acetyltransferase (SNAT).[23]  Oleoyl-CoA was shown to be a competitive inhibitor versus 
acetyl-CoA (Figure 2.4A) and a pure noncompetitive inhibitor against tryptamine (Figure 2.4B) 
with inhibition constants of 220 ± 20 μM and 790 ± 30 μM, respectively.  Tyrosol displayed 
uncompetitive inhibition versus acetyl-CoA (Figure 2.4C) and was shown to be a competitive 
inhibitor against tryptamine (Figure 2.4D), with inhibition constants of 230 ± 10 μM and 90 ± 10 
μM, respectively.  These inhibition patterns indicate the generation of N-acetyltryptamine 
catalyzed by Bm-iAANAT3 follows an ordered sequential mechanism, with acetyl-CoA binding 
 
 50 
 
first followed by tryptamine to form a ternary complex (Bm-iAANAT3•acetyl-CoA•tryptamine) 
before catalysis can transpire.  A similar kinetic mechanism was elucidated for sheep SNAT[24] 
and several D. melanogaster AANATs.[14, 22] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Dead-end inhibition plots for Bm-iAANAT3.  (A) Velocities measured at a fixed 
concentration of tryptamine (100 µM) with varied concentrations of acetyl-CoA (10 µM, 25 µM, 50 µM, 
and 100 µM), at varied concentrations of the inhibitor, oleoyl-CoA: 0 nM (), 250 nM (), and 500 nM 
(); Ki = 220 ± 20 μM  (B) Velocities measured at a fixed concentration of acetyl-CoA (100 µM) with 
varied concentrations of tryptamine (50 µM, 100 µM, 150 µM, and 300 µM), at varied concentrations of 
the inhibitor, oleoyl-CoA: 0 nM (), 250 nM (), and 500 nM (), Ki = 790 ± 30 μM  (C) Velocities 
measured at a fixed concentration of tryptamine (100 µM) with varied concentrations of acetyl-CoA (10 
µM, 25 µM, 50 µM, and 100 µM), at varied concentrations of the inhibitor, tyrosol: 0 µM (), 150 µM 
(), and 300 µM (); Ki = 230 ± 10 μM  (D) Velocities measured at a fixed concentration of acetyl-CoA 
(100 µM) with varied concentrations of tryptamine (50 µM, 100 µM, 150 µM, and 300 µM), at varied 
concentrations of the inhibitor, tyrosol: 0 µM (), 150 µM (), and 300 µM (); Ki = 90 ± 10 μM   
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 Following our inhibition studies, we assayed the pH-dependence on the kinetic constants 
of Bm-iAANAT3 for acetyl-CoA to determine the apparent pKa of the catalytic amino acid 
residues.  Both the kcat,app and (kcat/Km)app pH-rate profiles exhibited a rising conformation with 
pKa,app values of 6.9 ± 0.2 and 6.7 ± 0.1, respectively (Figure 2.5) 
 
 
 
 
 
Figure 2.5 pH rate profiles for Bm-iAANAT3. (A) log kcat versus pH for acetyl-CoA. (B) log 
(kcat/Km) versus pH for acetyl-CoA. 
 
An apparent pKa of ~6.8 can be ascribed to a general base in catalysis.  This pKa value likely 
corresponds to the general base deprotonating the primary amine of tryptamine; alternatively, it 
could be attributed to the zwitterionic tetrahedral intermediate that is produced after the 
nucleophilic attack of the acetyl-CoA thioester by tryptamine.  This experiment did not explicate 
a second, higher pKa value; this additional pKa (~8.5 – 10.0) would correspond to a general acid 
in catalysis, routinely observed for NAT enzymes.[13, 22, 25]  We hypothesize that Bm-iAANAT3 
either lacks a general acid in catalysis, or the general acid has a pKa value > 9.5, a number too 
high for us to ascertain due to limitations of acetyl-CoA hydrolysis and/or DTNB instability at 
elevated pH ranges. 
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Finally, in order to implicate catalytically-relevant amino acid residues, we produced a 
site-directed alanine mutant of Glu-27, the probable general base in catalysis.  This glutamate 
residue is highly conserved in insect AANAT enzymes (as illustrated in the second row of the 
homology overlay in Figure 2.2), and has been proposed as the general base in several 
mechanistic studies.[14, 22]  The E27A mutant enzyme was cultured, purified, and characterized in 
the same manner as the wild-type Bm-iAANAT3.  When assayed, this mutant only maintained 
0.06% to 0.13% the kcat,app value compared to wild-type, in addition to exhibiting a 100-fold 
increase in the Km,app for tryptamine (Table 2.12).  The massive decline in catalytic activity as 
compared to wild-type Bm-iAANAT3, in addition to the large perturbation in the (Km,tryptamine)app, 
suggests that this residue functions as a general base in catalysis, as well as playing a role in 
substrate binding.  Glu-27 likely represents the pKa,app value of 6.8 observed in the pH-rate 
profile (Figure 2.5) 
 
Table 2.12 Steady-state kinetic constants for the E27A Bm-iAANAT3 mutant. 
 
 
 
 
 
 
 
Acetyl-CoA 
Enzyme 
Km, app 
(μM) 
kcat, app 
(s-1) 
(kcat/Km)app 
(M-1 s-1) 
% Enzyme 
Activity 
Wild-Type 90 ± 3.6 64 ± 1.0 (7.1 ± 0.3) x 105 100 
E27A 20 ± 2.2 0.04 ± 0.0009 (2.0 ± 0.2) x 103 0.28 
Tryptamine 
Enzyme 
Km, app 
(μM) 
kcat, app 
(s-1) 
(kcat/Km)app 
(M-1 s-1) 
% Enzyme 
Activity 
Wild-Type 97 ± 8.8 60 ± 1.2 (6.2 ± 0.6) x 105 100 
E27A 9400 ± 990 0.08 ± 0.003 8.8 ± 1.0 0.0014 
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When taken together, our data strongly supports the mechanism depicted in Figure 2.6.  
The double-reciprocal plots and dead-end inhibition analysis indicate an ordered sequential 
mechanism: acetyl-CoA binds first, followed by tryptamine, thus forming a ternary complex 
(Bm-iAANAT3•acetyl-CoA•tryptamine) before catalysis occurs.  Once both substrates are bound 
to the active site, a general base (Glu-27) deprotonates the positively charged amine moiety of 
tryptamine through ordered water molecules, with subsequent nucleophilic attack on the 
carbonyl of the acetyl-CoA thioester.  This forms a zwitterionic tetrahedral intermediate, which 
collapses as the coenzyme A thiolate is protonated by the positively charged amine of the 
intermediate.  We propose an ordered product release, with N-acetyltryptamine first exiting, 
followed by coenzyme A.  Future experimentation with ITC or intrinsic tryptophan fluorescence 
testing the direct binding affinity of the free SH-CoA to Bm-iAANAT3 in the presence and 
absence of N-acetyltryptamine should confirm this hypothesis.  This mechanism is consistent 
with other previously studied AANAT kinetic mechanisms.[14, 26] 
 
 
 
 
 
 
Figure 2.6 Proposed mechanism for the N-acetylation of tryptamine by Bm-iAANAT3. 
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2.4 Discussion and Conclusions 
Understanding AANAT enzymes is of great scientific and economical importance.  In 
this study, we have successfully cloned, expressed, and purified a pair of AANAT enzymes from 
Bombyx mori, and discovered several novel substrates for each.  Notably, we have identified the 
facility of Bm-iAANAT to catalyze the conjugation of long-chain N-acylarylalkylamides, only 
the second enzyme of its kind ascertained to date (the first being Dm-AANATL2).[16]   Bm-
iAANAT may be the biological source of these potent neurotransmitters in vivo, while the 
second enzyme we studied could be responsible for the inactivation of the biogenic amines in B. 
mori.  Bm-iAANAT3, a previously unstudied enzyme, displayed broad substrate specificity with 
catalytic rates approaching 600x that of Bm-iAANAT.  For this reason, we postulate Bm-
iAANAT3 may play a greater role in regards to acetylating the arylalkylamides, while Bm-
iAANAT is a versatile, multifaceted “generalist” enzyme in the silkworm.  Bm-iAANAT is 
capable of acylating a broad range of amines with either short or long-chain acyl-CoAs, while 
Bm-iAANAT3 inactivates amines in a limited capacity, albeit in a far more potent manner. 
In addition to our kinetic investigations into these AANAT enzymes, we have also begun 
crystallography and inhibition studies (data not shown; pending publication). Due to the role of 
AANAT in insect sclerotization, circadian entrainment, melanism, monoamine catabolism, and 
melatonin production, it could prove to be an ideal target for the development of insecticides for 
pest management.  Several groups have successfully produced recombinant iAANAT variants 
and screened them against chemical libraries to deduce compounds of high inhibitory affects.   
Several were identified by the Tsugehara group that registered as herbicidal and miticidal agents, 
acting as an acetyl-CoA carboxylase inhibitor and cuticle-penetrating toxin, respectively.[12, 27]  
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Neither of these compounds displayed inhibition against sheep AANAT, proof positive that the 
iAANAT enzymes share little homology with their mammalian counterparts. 
Another intriguing possibility for pest control is the utilization of specific wavelengths of 
light. For instance, it was demonstrated that the two spotted spider mite will avoid UV-blue 
light.[6] The illumination of the mite to short-wave light affects mortality through increased ROS 
damage (less production of the ROS scavenger melatonin) while disrupting cuticle formation, the 
rate of oviposition, the inability to detoxify monoamine neurotransmitters, and photoperiodism.  
If these compounds ultimately inhibit vertebrate AANAT enzymes, they could be utilized as 
drugs that modulate endocrine function, sleep disorders, regulate mood and behavior through 
pineal melatonin biosynthesis, and could also be used to improve vision by promoting the 
detoxification of amines in the retina.[27-30] 
We have also made great strides with crystallography studies, with a pending publication 
regarding the crystal structure of Dm-AANATL8 from D. melanogaster.  Our hope is that we 
can not only gain a better understanding of the amino acids implicated in enzymology (which 
will in turn lead to a better understanding of the AANAT-catalyzed mechanism), but to also 
begin docking studies.  We hope to elucidate tight binding bisubstrate analogs that could serve as 
a platform for the creation of new activity based probes (ABP).  Since there is little conserved 
homology in the sequences of these enzymes from different organisms, we could use these 
probes to enrich previously undiscovered mammalian AANAT orthologs.  The study of these 
novel enzymes would have vast implications for furthering the understanding of the human 
brain, and the proteins and neurotransmitters that dictate a plethora of biophysical processes.  
Our lab has extensive experience with the design and implantation of ABPP probes, which is the 
focus of the work in Chapter 3. 
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CHAPTER THREE: 
A FACILE, MICROWAVE-ASSISTED SYNTHESIS OF AN ADENOSINE-RIBOSE 
PROBE FOR BINDING-BASED PROFILING OF NUCLEOSIDE AND NUCLEOTIDE-
BINDING PROTEINS 
 
3.1 The Profiling of AdoR-Binding Proteins with a Novel Binding-Based Probe 
Since the advent of genome mapping and the accessibility of complete genomic 
sequences for various model organisms, the field of proteomics emerged to develop and apply 
methods for the analysis of large numbers of proteins expressed by these genes.  Proteomics can 
be defined as the qualitative and quantitative comparisons of the protein products of organisms 
under different conditions or stresses.[1] Proteomic analysis is inherently difficult because the 
varying amounts of proteins expressed at a given time fluctuate greatly within a cell. In addition, 
many other factors can contribute to analytical difficulties such as low expression, the varying 
chemical properties of different cell types, location of the proteins (membrane-bound, 
cytoplasmic, etc), the presence of post-translational modifications, and a lack of propagation 
techniques such as the polymerase chain reaction.[1] 
One such pioneering technique to overcome these technical challenges is activity-based 
protein profiling (ABPP) which uses small molecules known as ABPP probes that covalently 
bind to the catalytic site of specific targeted proteins acquired from cells, tissues, and even entire 
organisms.  Typically, these ABPP probes possess a “chemical warhead” that modifies the target 
protein by reacting with a catalytically relevant active site nucleophile or electrophile to provide 
 
 
62 
 
a measure of enzyme activity. ABPP probes are also designed to incorporate a chemical handle 
that facilitates the identification and/or the purification of probe-modified proteins.[2] The probe-
based purification/enrichment process allows for the screening and detection of low-abundant 
proteins, and can be used in addition to subcellular fractionation. 
Specific ABPP probes have targeted different enzyme classes found within complex 
proteomic systems: proteases, phosphatases, glycosidases, hydrolases, metalloproteases, kinases, 
oxidoreductases, and proteasomal subunits.[3-4] The work we detail here describes the 
development and utilization of a binding-based proteomic profiling probe (BBPP) that enriches 
proteins that bind the adenine nucleosides and nucleotides (known as adenine ribose derivatives, 
or AdoRs).  Adenine nucleosides and nucleotides are endogenous purines that play vital roles in 
biological systems, including DNA and RNA biosynthesis, signaling molecules such as 
adenosine or cyclic adenosine monophosphate (cAMP), and as components of the cellular energy 
currency in the form of the mono-, di- and triphosphates of adenosine (AMP, ADP, and ATP).[5]  
There are numerous proteins in the cell that bind AdoRs, with various AdoR derivatives acting as 
enzyme substrates, products, intermediates, coenzymes, or even as allosteric activators and 
inhibitors.[6] The AdoR-binding proteome is easily one of the largest (over half of the human 
proteome binds some form of nucleotide),[7] with aberrant or defective expression of many of 
these proteins and enzymes being correlated to different diseases. This indicates the AdoR-
binding proteome is an excellent target for the study of ABPP and BBPP technology, leading to 
the discovery of novel biomarkers for the early diagnosis and evaluation of biological disorders. 
Previously published work from our lab entailed the conception and development of an 
adenosine-based BBPP probe for the selective targeting of AdoR-binding proteins with 
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alterations on the purine ring at the N6- and C8- positions, as opposed to the more common 
derivatization site on the 5’-hydroxl of the ribose sugar.[8] This probe, N6-[6-
(biotinamido)hexyl]-8-azidoadenosine, is shown in Figure 3.1.  
 
 
 
 
 
Figure 3.1 The N6-Biotinylated-8-azidoadenosine activity based probe. 
This BBPP probe includes an adenosine moiety for targeting the AdoR-binding proteins, 
a photo-activatable azide which covalently binds the protein when UV irradiated, and a biotin tag 
used for isolation and detection of the probe-labeled proteins. However, synthesis of N6-
biotinylated-8-azido-adenosine is tedious: an 8-step synthetic protocol with an overall yield of 
10-15%, including a preparative HPLC purification step for a synthetic intermediate and the 
detailed monitoring of the azidoylation step by LC-MS.[8] We report here on a novel synthetic 
protocol utilizing microwave irradiation to simplify the preparation of N6-[6-
(biotinamido)hexyl]-8-azidoadenosine to better supply this probe for proteomic profiling 
applications. Given an improved and less expensive route to N6-[6-(biotinamido)hexyl]-8-
azidoadenosine, we used this to interrogate the AdoR-binding proteome of several different 
species of Bacillaceae.  Members of the family Bacillaceae consist of gram-positive, rod-shaped 
bacteria that are genotypically and phenotypically heterogeneous, with many capable of 
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producing endospores. These bacteria represent microbes of high economic, medical, and 
military importance, used to produce biofuels, biopesticides, bioweapons, and even probiotics.[9]  
 
3.2 Materials and Methods 
A bacterial-specific protease inhibitor cocktail (Sigma: P8465) and anti-biotin antibody 
HRP conjugate were purchased from Sigma Aldrich.  Monomeric avidin agarose, SuperSignal 
West Pico Chemiluminescent Substrate, and CL-XPosure film were purchased from Thermo 
Scientific. Bacillus subtilis (ATCC 6051), Bacillus stearothermophilus (Geobacillus 
stearothermophilus ATCC 7953), and Bacillus globisporus (Sporosarcina globispora ATCC 
23301) were all purchased from ATCC.  Microwave irradiation experiments were conducted in 
an Anton Paar microwave reactor (Monowave 300).  All other reagents and supplies were of the 
highest quality available from commercial suppliers. 
 
3.2.1 Synthesis of the Activity Based Probe 
3.2.1.1 Synthesis of  Compound 4: 2-(acetoxymethyl)-5-(6-((6-aminohexyl)amino)-8-bromo-9H-
purin-9-yl)tetrahydrofuran-3,4-diyl diacetate 
Compound 3 (2’,3’,5’)-triacetyl-8-bromoinonsine) was prepared from commercially 
available inosine as described. [8] Compound 3 (500 mg, 1.06 mmol) and PyBroP (1.05 eq: 520 
mg, 1.12 mmol) were reconstituted with dry dichloromethane (DCM) and 8 equivalents (1.48 
mL) of N,N-diisopropylethylamine (Hünig's base or DIPEA), while maintaining dry conditions.  
Reagents were transferred to a 30 mL microwave reaction vessel with appropriate stir bar, 
capped, and reacted in the microwave for 5 minutes at 1200 RPM, 30 bar (435 PSI), and 120°C 
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to form the phosphonium intermediate. Immediately after cooling,  
1,6-diaminohexane (4 eq: 490 mg, 4.31 mmol) was slowly injected into the solution, ensuring 
complete transfer.  The tube was re-capped and reacted in the microwave for an additional 10 
minutes at 1200 RPM, 30 bar (435 PSI), and 120°C.  After completion of microwave irradiation, 
an equal amount of water was added and mixed well to resolubilize the precipitated amine 4. 
The reaction solution was extracted 2-3 times in DCM and water.  The DCM extract was 
taken to dryness using a rotary evaporator.  Crude amine 4 was redissolved in  2 mL of 50:50 
water and methanol and purified by reverse-phase column chromatography (RP-HPLC) using an 
Agilent Eclipse XDB-C18 column (5 m, 9.4 mm × 250 mm) on a Waters Prep LC 4000 system 
interfaced with 996 photo-diode array detector.    Amine 4 was eluted at 52:48 A:B using a linear 
gradient of A:B (70:30 to 0:100) over 40 min at a flow rate of 5.0 mL/min, where solvent A was 
H2O and solvent B was acetonitrile.  Fractions containing amine 4 were combined, the volume 
reduced to ~5 mL using a rotor evaporator, and, lastly, the solvent completely removed by 
lyophilization.  258 mg purified; 43% yield. 
LC-MSD m/z observed: 571.1. 1H NMR (400 MHz, cdcl3) δ 10.92 (s, 2H), 8.25 (s, 2H), 6.33 – 
6.28 (m, 1H), 6.05 (d, J = 4.4 Hz, 2H), 5.91 (t, J = 5.9 Hz, 2H), 4.51 – 4.27 (m, 6H), 3.69 – 3.64 
(m, 19H), 3.42 (d, J = 7.3 Hz, 4H), 3.08 (d, J = 7.4 Hz, 19H), 2.94 – 2.89 (m, 7H), 2.16 (s, 4H), 
2.12 (s, 6H), 2.07 (s, 6H), 2.01 (s, 8H), 1.92 (s, 7H), 1.80 – 1.76 (m, 1H), 1.66 (s, 4H), 1.59 (s, 
3H), 1.43 (s, 3H), 1.42 (s, 2H), 1.39 (s, 4H). 
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3.2.1.2 Synthesis of Compound 5: 2-(acetoxymethyl)-5-(6-((6-aminohexyl)amino)-8-azido-9H-
purin-9-yl)tetrahydrofuran-3,4-diyl diacetate 
Amine 4 (156 mg, 0.27 mmol) was reconstituted with 1 mL dry dimethylformamide 
(DMF) per 50 mg of starting material, to which was added 100 L of water containing 10 
equivalents of NaN3 (178 mg).  The reaction mixture was microwave irradiated for 10 minutes at 
120°C, 1200 RPM and 30 bar (435 PSI) in a small reaction vessel.  Product was extracted in 
DCM and brine, which greatly helped disperse the water/DMF emulsion. Compound 5 was 
purified by RP-HPLC, as described by Mahajan et al. [8] 120 mg purified; 72% yield. 
LC-MSD m/z observed: 534.2.  1NMR is identical to compound 9. 
 
3.2.1.3 Synthesis of Probe 7: N6-[6-(biotinamido)hexyl]-8-azidoadenosine 
Methods for the biotinylation of compound 5 to yield compound 6 followed by 
deprotection of 6’-hydroxyl for production of the desired BBPP probe 7 have been described 
previously.[8] 
 
3.2.2 Growth of Bacterial Cells for Use in BBPP Studies 
Small aliquots of each lyophilized cell line were reconstituted in sterile tryptic soy broth 
(TSB) and grown overnight at the optimal temperature to amass the required concentration of 
cells needed for glycerol stocks.  Bacillus subtilis was grown at 37°C for 24 hours, Geobacillus 
stearothermophilus at 55°C for 48 hours, and Sporosarcina globispora at 15°C for 72 hours.  
These stocks were then plated on agar to ensure viable growth and single-colony purity.  
Genuine colonies were used to make overnight broth cultures. A 3-hour growth was initiated in 
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fresh broth, and then each bacterial species was standardized to an optical density value (OD600) 
of 0.05 in new flasks.  OD600 readings were then taken every hour for 8 hours, then again after 
24, 48 and 72 hours, and this data was used to generate bacteria-specific growth curves (OD600 
vs. time, data not shown).  Given the growth curves for each bacterial species, we used these data 
to harvest the bacterial cells in the exponential phase to ensure standardization.    
 Large scale liquid cultures (100 mL) in media broth were grown to the exponential 
phase, harvested by centrifugation, and washed once with PBS.  The cell pellets were 
resuspended in cell lysis buffer containing 20 mM Tris HCl (pH 7.4), 2 mM MgCl2•6H20, 1 mM 
EDTA, 2 mM EGTA, 150 mM NaCl, 1.0% TX-100, 1 mM PMSF, and 10 µL bacterial protease 
inhibitor cocktail (Sigma Aldrich: P8340) per 1 mL cell solution. 1 mL aliquots of cells were 
dispensed into Eppendorf tubes, and 100 µg of 0.1 mm glass lysing beads were added to each.  
Tubes were placed in a bead beater and shaken at 4°C for four 60 second cycles.  The tubes 
containing crude cellular lysates were centrifuged twice at 13,400 RPM for 10 minutes, saving 
the supernatant.  These supernatant fractions constituted the soluble proteome from each 
bacterial species, and were stored at -80°C until evaluated using our BBPP probe.  Protein 
concentrations were determined using the Bradford dye-binding assay.[10] 
 
3.2.3 Enrichment of AdoR-Binding Proteins and Subsequent Qualitative Analysis via 
SDS-PAGE and Western Blots 
To qualitatively assess the AdoR-binding proteome of several bacterial cell lines, an 
enrichment protocol was adopted from the work of Mahajan, et al. [8] The soluble proteomes 
from the cellular lysates of B. subtilis, G. stearothermophilus, and  
S. globispora were irradiated with ultraviolet light (295 nm) in the presence of BBPP probe 7 for 
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2 minutes with intermittent stirring, at a ratio of 200 µM probe per 1 mg of proteome solution.  
The resultant mixture of proteins and [protein + probe] conjugates was subjected to monomeric-
avidin column chromatography to first elute non-bound proteins with PBS buffer (proteins that 
have not been tagged by the probe and, thus, are not likely members of the adenosine-binding 
proteome).  This elution fraction was designated as the “PBS Wash”.  Next, weakly bound 
proteins (and thus, probe-affixed proteins) were eluted with a 2 mM biotin buffer, which acts as a 
competitive affinity-binding agent for the avidin stationary phase, and is referred to as the 
“Biotin Wash” fraction.  Finally, the column is washed with a 0.1 M glycine buffer (pH 2.8) 
which alters the avidin structure, disrupting the interaction between avidin and biotin.  This 
elution fraction is referred to as the “Regeneration Wash”, and thus constitutes the majority of 
the AdoR-binding proteome from the cell lysates.  Similar fractions were combined and reduced 
over 10 kDa filters, and subjected to SDS-PAGE analysis in duplicate.  The protein profiles were 
further characterized by qualitative Western blot analysis; the Western blots were incubated with 
an anti-biotin HRP-conjugated antibody, so that only biotinylated proteins (tagged proteins) 
would be detected.  The membrane was then developed using SuperSignal West Pico 
Chemiluminescent Substrate and exposed to CL-Xposure film.  A full discussion of the 
enrichment protocol is detailed in the work by Mahajan, et al.[8] 
 
3.3 Experimental Results 
3.3.1 Synthesis of the AdoR-Binding Probe 
The precedent protocol for the synthesis of N6-[6-(biotinamido)hexyl]-8-azido-adenosine 
(Figure 1) is outlined in the work by Mahajan et al.[8] Inosine, an adenosine analog, is used as the 
starting material and is first protected at the hydroxyl positions on the ribose ring with acetic 
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anhydride and 4-dimethylaminopyridine (DMAP) in anhydrous DCM to yield a triacetyl 
derivative.[11-12] The C8-position of the purine ring is then brominated using a saturated bromine 
solution in 10% sodium phosphate,[13] followed by subsequent chlorination using thionyl 
chloride under reflux to produce the 6,8-dichloro derivative.[14] Selective substitution of the 
linker group (N-Boc-1,6-diaminohexane) was introduced at the N6-position at 0°C, with roughly 
20% of the reaction being aminated at the C8-position as a side product.  Replacement of the 
chlorine atom at C8 with azide was achieved by refluxing for 5 days with cesium azide (CsN3) 
and trimethylsilane azide (TMS-N3) in a dioxane/water solution.  Deprotection of the N-Boc 
group was accomplished using trifluoroacetic acid in DCM at room temperature, with 
subsequent biotinylation using EDCI/DMAP coupling.  Finally, a selective mono-deprotection 
was conducted on the acetyl group at the 5’-position in an ammonia/methanol solution at -40°C, 
providing the final AdoR-binding BBPP probe. We avoided the complete deprotection of the 
ribose hydroxyls because such a BBPP would result in the enrichment of too great a number of 
proteins for effective analysis; hence, the protecting acetyl groups were left to decorate the 2’ 
and 3’-hydroxyl of the ribose ring in our final BBPP probe. 
The most significant synthetic challenge in producing our desired BBPP probe is the di-
substitution at the N6 and C8-positions of the purine.  Typically, nucleophilic displacement of the 
N6-halogen atom with an amine occurs via a SNAr mechanism, a reaction that requires the initial 
formation of the dichloro derivative (see compound 4 in the work of Mahajan et al).  To 
overcome this obstacle, attempts to directly aminate the purine at the N6-position without a 
halogen leaving group were pursued using the coupling reagent (benzotriazol-1-
yloxy)tris(dimethylamino) phosphonium hexafluorophosphate (BOP, as depicted in Figure 3.2) 
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in DMF and DIPEA, as detailed in the literature.[15] However, this synthesis was unsuccessful, 
most likely due to the presence of the bromine substitution at the C8-position.  
 
 
 
 
 
Figure 3.2 The coupling reagent BOP, initially used in attempts to directly aminate the AdoR-
binding ABP. 
 
 
Recent work by Ashton and coworkers was successful in this directed amination using 
bromo-tris-pyrrolidino phosphoniumhexafluorophosphate (PyBroP) in place of BOP under 
microwave conditions, during which the reaction would proceed solely through a phosphonium 
intermediate to yield the desired N6-substituded nucleoside.[16] This reaction mechanism is 
illustrated in Figure 3.3. The PyBroP- utilized synthetic protocol is also advantageous since it 
alleviates the undesirable amination at the C8-position, eliminating a major side product that is 
difficult to remove. The novel synthetic approach to synthesize the desired BBPP probe 
(compound 7) using microwave irradiation is detailed in Figure 3.4.  
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Figure 3.3 PyBroP and the mechanism of direct amination on the N6-position of a nucleoside 
proceeding through a phosphonium intermediate. 
 
Direct amination was first attempted using the linker moiety, N-Boc-1,6-diaminohexane.  
While this protected amine provided sufficient yields of the desired product, its relatively high 
cost limited the amount of bulk probe that could be synthesized. Using the less expensive 
unprotected 1,6-diaminohexane as an alternative linker, we found that microwave-assisted 
PyBroP amination was successful, yielding compound 4 (43% yield).  Another advantage of 
using 1,6-diaminohexane as the linker is a simpler synthetic strategy because its use eliminates 
the amine deprotection step prior to biotinylation.  
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Figure 3.4 The microwave-assisted synthetic protocol of the AdoR-binding ABP (probe 7).  This 
method allows for a reduced cost of synthesis and abbreviated reaction times. 
 
Upon addition of the deprotected aminated linker chain, displacement of the bromine at 
the C8-location with the photo-activatable azide was attempted to yield compound 5.   Typically, 
this is a straightforward synthesis, utilizing CsN3 and TMS-N3 under standard reflux conditions 
in DMF for several days.  However, the alternative linker with a primary amine posed problems; 
the free amine serving as a nucleophile deprotected the ribose ring leading to several undesirable 
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side products.  Accordingly, we developed a new method to install the azide at C8 of ribose, 
which would reduce the amount of time the amine could deprotect the BBPP probe and would 
eliminate the use of the costly CsN3.   
We proposed that microwave irradiation would, again, solve our problems in the desired 
azidylation of C8.  Azides are considered good nucleophiles and can readily displace halides; 
however, the reaction is often very slow, and prolonged exposure to high heat under reflux can 
result in the decomposition of the azide (or worse, an explosion).  The acceleration of this 
reaction can be achieved using microwave conditions, demonstrated by the several groups that 
had considerable success using domestic microwave ovens to produce azido-compounds in 
drastically reduced times in similar yields to conventional heating.[17-18] Building upon this work, 
the azidylation reaction was optimized using DMF and NaN3.  Compound 5 was successfully 
synthesized in yields up to 72%, and after HPLC purification, was converted to compound 6 with 
the same EDCI/DMAP coupling reaction as reported in the original synthetic protocol.  Similar 
yields were achieved in producing probe 7 using our new synthetic strategy incorporating 
microwave irradiation in two steps, significantly reducing both the time and cost required to 
synthesize the desired BBPP probe.   
 
3.3.2 Western Blot Analysis of the AdoR-Binding Proteome 
To demonstrate the utility of the AdoR-directed BBPP probe synthesized using the 
strategy outlined here, we used probe 7 to generate profiles from three microorganisms: 
Sporosarcina globispora (a psychrophile), Bacillus subtilis (a mesophile), and Geobacillus 
stearothermophilus a (a thermophile) (Figure 3.5).   
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Figure 3.5 The proteomic profiles of B. subtilis (mesophile) compared to two extremophiles, G. 
stearothermophilus (thermophile) and S. globispora (psychrophile).  SDS-PAGE analysis in 
pane (a) and Western blots in pane (b).  Their profiles are quite dissimilar, indicating they 
achieve metabolism with different types and quantities of adenine and adenosine-binding 
proteins. 
 
The proteomic profiles resulting from our use of probe 7 were analyzed by SDS-PAGE in 
two ways: total protein analysis by staining with Coomassie Brilliant Blue (Figure 3.5, panel A), 
and Western blot analysis using an anti-biotin antibody (Figure 3.5, panel B). The molecular 
weight markers are shown in Lane 1, while Lanes 2 through 4 constitute the PBS Wash fractions 
representing the unbound, non-tagged proteins. This group of proteins are not observed by 
Western analysis (Figure 3.5, panel B).  These proteins largely represent the non-AdoR-binding 
proteins and comprise the most abundant fraction of the soluble cellular proteome (~70-80% of 
the total soluble cellular proteome).  The Biotin Wash, Lanes 5 to 7, is composed of the protein 
eluted with 2.0 mM biotin.  The Regeneration Wash, Lanes 8 to 10, contains the proteins most 
tightly bound to the avidin column and were only eluted using a pH 2.8 wash solution that 
disrupts the avidin-biotin interaction and restores the ability of avidin to bind biotin.  The 
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proteins found within both the Biotin Wash and Regeneration Wash are AdoR-binding proteins, 
representing ~20-30% of the total soluble cellular proteome. The Biotin Wash possesses the 
lowest percentage of total soluble cellular proteome, 5-10%.  Note that our data are consistent 
with a previous estimate that AdoR-binding proteins represent ~25% of the total cellular 
proteome[8] and, intuitively, it seems logical that the Biotin Wash (AdoR-binding proteins with 
relatively low affinity for biotin) would contain the smallest percentage of total soluble 
proteome. 
The patterns evident in panels A and B of Figure 3.5 demonstrate that our BBPP probe 
works well to generate defined proteomic profiles for the comparison of AdoR-binding protein 
profiles between different organisms.  By extension to these data, our BBPP probe would prove 
valuable in defining and comparing AdoR-binding proteins between other related samples, 
including cell lines, tissues, and disease states.  The data shown in Figure 3.5 hint at intriguing 
differences between the microorganisms because we loaded the same amount of total protein  
(10 g) in each lane.  More detailed and quantitative studies performed by growing the different 
bacteria in SILAC media, with subsequent proteomic analysis using high resolution mass 
spectrometry, would allow us to completely “mine” the data revealed by our BBPP probe.  Such 
work is beyond the scope of the project detailed herein. 
 
 
3.4 Conclusion 
Binding-based proteomic profiling is a natural extension from activity-based proteomic 
profiling and will aid in the identification of important non-enzyme proteins, including receptors, 
regulatory proteins, and structural proteins.  Critical to the success of BBPP is the design and 
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synthesis of useful BBPP probes.  We describe here an improved strategy for the synthesis of 
BBPP probes based on adenosine and the adenylate nucleotides (AdoRs).  Our synthetic scheme 
incorporates microwave irradiation at two steps relative to a previous reportedly strategy[8] 
yielding a streamlined and more cost efficient route to the desired BBPP probe, compound 7.  
Use of the BBPP probe produced by our improved protocol yields distinctive proteomic profiles 
that point towards differences in the profiles of AdoR-binding proteins between related 
psychrophilic, mesophilic, and thermophilic bacteria (Figure 3.5). The proteomic profiles 
reported herein in combination with those published earlier using the same BBPP probe 
demonstrate that compound 7 is useful in defining proteomic profiles for the comparison AdoR-
binding proteins between different, biologically relevant samples.   
 
3.5 References 
[1] Hagenstein, M. C.; Sewald, N., Chemical tools for activity-based proteomics. Journal of 
Biotechnology 2006, 124 (1), 56-73. 
[2] Paulick, M. G.; Bogyo, M., Application of activity-based probes to the study of enzymes 
involved in cancer progression. Current Opinion in Genetics & Development 2008, 18 
(1), 97-106. 
[3] Jessani, N.; Cravatt, B. F., The development and application of methods for activity-
based protein profiling. Current Opinion in Chemical Biology 2004, 8 (1), 54-59. 
[4] Barglow, K. T.; Cravatt, B. F., Discovering disease-associated enzymes by proteome 
reactivity profiling. Chemistry & Biology 2004, 11 (11), 1523-1531. 
 
 
77 
 
[5] Samsel, M.; Dzierzbicka, K., Therapeutic potential of adenosine analogues and 
conjugates. Pharmacol. Rep. 2011, 63 (3), 601-617. 
[6] Moodie, S. L.; Mitchell, J. B. O.; Thornton, J. M., Protein recognition of adenylate: An 
example of a fuzzy recognition template. J. Mol. Biol. 1996, 263 (3), 486-500. 
[7] Cravatt, B. F.; Wright, A. T.; Kozarich, J. W., Activity-based protein profiling: From 
enzyme chemistry. In Annual Review of Biochemistry, Annual Reviews: Palo Alto, 2008; 
Vol. 77, pp 383-414. 
[8] Mahajan, S.; Manetsch, R.; Merkler, D. J.; Stevens Jr, S. M., Synthesis and Evaluation of 
a Novel Adenosine-Ribose Probe for Global-Scale Profiling of Nucleoside and 
Nucleotide-Binding Proteins. PLoS One 2015, 10 (2), e0115644. 
[9] Porwal, S.; Lal, S.; Cheema, S.; Kalia, V. C., Phylogeny in Aid of the Present and Novel 
Microbial Lineages: Diversity in Bacillus. PLoS One 2009, 4 (2). 
[10] Bradford, M. M., A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Analytical 
Biochemistry 1976, 72 (1–2), 248-254. 
[11] Allerson, C. R.; Chen, S. L.; Verdine, G. L., A chemical method for site-specific 
modification of RNA: The convertible nucleoside approach. Journal of the American 
Chemical Society 1997, 119 (32), 7423-7433. 
[12] Xu, S. J.; Held, I.; Kempf, B.; Mayr, H.; Steglich, W.; Zipse, H., The DMAP-catalyzed 
acetylation of alcohols - A mechanistic study (DMAP=4-(dimethylamino)pyridine). 
Chem.-Eur. J. 2005, 11 (16), 4751-4757. 
 
 
78 
 
[13] Roelen, H.; Veldman, N.; Spek, A. L.; Kunzel, J. V. D.; Mathot, R. A. A.; Ijzerman, A. 
P., N-6,C8-disubstituted adenosine derivatives as partial agonists for adenosine A(1) 
receptors? Journal of Medicinal Chemistry 1996, 39 (7), 1463-1471. 
[14] Szekeres, G. L.; Robins, R. K.; Boswell, K. H.; Long, R. A., Synthesis of 8-amino-9-
beta-D-ribofuranosylpurin-6-thione and Related 6-substituted-8-aminopurine 
Nucleosides. Journal of Heterocyclic Chemistry 1975, 12 (1), 15-19. 
[15] Wan, Z. K.; Binnun, E.; Wilson, D. P.; Lee, J., A highly facile and efficient one-step 
synthesis of N-6-adenosine and N-6-2 '-deoxyadenosine derivatives. Organic Letters 
2005, 7 (26), 5877-5880. 
[16] Ashton, T. D.; Scammells, P. J., Microwave-assisted direct amination: Rapid access to 
multi-functionalized N-6-substituted adenosines. Australian Journal of Chemistry 2008, 
61 (1), 49-58. 
[17] Park, S. H., Acceleration of azidation by microwave irradiation. Bull. Korean Chem. Soc. 
2003, 24 (2), 253-255. 
[18] Lucas, R.; Neto, V.; Bouazza, A. H.; Zerrouki, R.; Granet, R.; Krausz, P.; Champavier, 
Y., Microwave-assisted synthesis of a triazole-linked 3 '-5 ' dithymidine using click 
chemistry. Tetrahedron Lett. 2008, 49 (6), 1004-1007. 
 
 
79 
 
 
 
 
CHAPTER FOUR: 
MECHANISTIC BINDING INSIGHTS FOR 1-DEOXY-D-XYLULOSE-5-PHOSPHATE 
SYNTHASE, THE ENZYME CATALYZING THE FIRST REACTION OF  
ISOPRENOID BIOSYNTHESIS IN THE MALARIA-CAUSING PROTISTS,  
PLASMODIUM FALCIPARUM AND PLASMODIUM VIVAX 
 
4.1 The Threat of Malaria, Isoprenoid Biosynthesis, and the Non-Mevalonate Pathway 
 
Malaria is a life-threatening, infectious disease caused by parasites of the genus 
Plasmodium, transmitted through the bite of an infected female Anopheles mosquito.  Malaria 
afflicts nearly 100 countries worldwide, with estimates of 198 million cases in 2013, resulting in 
584,000 deaths.[1] Malaria poses a risk to roughly half of the population on earth, and infections 
are on the rise due to global warming, deforestation, and drug and insecticide resistance. [1-5]   In 
humans, malaria is caused by an infection by one of five Plasmodium species: P. falicparum, P. 
vivax, P. ovale, P. malariae, and P. knowlesi.  P. falciparum malaria, constituting approximately 
75% of the reported cases, is the most deadly form of malaria; however, P. vivax malaria, 
constituting approximately 20% of the reported cases, is serious and more widespread. [1, 6]   
Isoprenoids (or terpenoids) constitute one of the largest classes of complex, biologically-
active compounds, which serve diverse roles, functioning as cholesterol, hormones, fat-soluble 
hormones, carotenoids, pigments, and chlorophyll. [7-9]  Isoprene is a five-carbon skeleton that is 
the precursor of all isoprenoids through rearrangement, cyclization, and oxidation. [10]  Yet, 
isoprene itself is not used for the production of isoprenoids in vivo; instead the biological forms 
of isoprene are the two branched, phosphorylated five-carbon precursors, dimethylallyl 
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pyrophosphate (DMAPP) and isopentyl pyrophosphate (IPP).  For half a century, it was thought 
that the sole biosynthetic pathway of isoprenoid production was via the mevalonate pathway. [11]  
However, in 1996, Rohmer et al.[12] discovered that certain eubacteria, parasites, and several 
plants produce isoprenoids from a mevalonate-independent pathway.  This non-mevalonate 
(NMVA) biosynthetic route (also known as the 2-C-methyl-D-erythritol 4-phosphate [MEP] 
pathway) produces DMAPP and IPP from a set of orthogonal enzymes nonexistent in higher 
organisms and mammals. The NMVA pathway, therefore, represents a platform for the 
development of novel antimalarials and antibiotics to aid the treatment of human disease. [12]  
In Plasmodium parasites, as well as other organisms from the phylum Apicomplexa, the 
NMVA pathway produces DMAPP and IPP over seven successive enzymatic reactions.   The 
first committed step of the pathway is catalyzed by 1-deoxy-D-xyluose-5-phosphate 
reductoisomerase (DXR), which involves the NADPH-dependent rearrangement and two 
electron reduction of the linear 1-deoxy-D-xylulose-5-phosphate (DXP) to the branched-chain 
isoprenoid precursor MEP.  However, the enzyme catalyzing the first reaction of the pathway is 
also an attractive target for inhibitor development, 1-deoxy-D-xylulose-5-phosphate synthase 
(DXS).  DXS catalyzes the condensation of pyruvate and D-glyceraldehyde-3-phosphate (GAP) 
to produced CO2 and 1-deoxy-D-xylulose-5-phosphate (DXP), a  reaction that is the rate-limiting 
for the NMVA pathway  in several organisms as well as the branch point for B vitamin and 
isoprenoid biosynthesis. [13] DXS belongs to the family of enzymes that utilizes thiamine 
pyrophosphate (TPP) as a co-factor, and shares high homology with human transketolase, 
pyruvate dehydrogenase, and pyruvate decarboxylase. [14-15] Like these other TPP-dependent 
enzymes, DXS catalyzes decarboxylation and carboligation chemistry: a two-carbon 
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intermediate bound to TPP (hydroxyethyl-TPP) is condensed with an acceptor substrate (GAP) 
via nucleophilic addition to generate a new carbon-carbon bond yielding DXP. 
All TPP-dependent enzymes catalyze two successive half reactions. [16]  The first step 
involves the attack of an activated TPP ylide at the first substrate. [17]  The next step could occur 
via three distinct mechanisms. The most common is the classical ping-pong mechanism, in 
which the first product is released, forming a metastable enzyme-intermediate complex.  Product 
formation follows after binding of the second substrate.  Every TPP-dependent enzyme studied 
to date follows this mechanism, and has also been proposed for DXS from E. coli and H. 
influenza. [18] Another possibility for the second half reaction proceeds through an ordered 
mechanism, where the first product can only be released after the second substrate is bound to 
the active site.  The first substrate binds tightly and essentially irreversibly, while the second 
substrate can only bind to a pocket opened in the presence of the first substrate.  Carbon dioxide 
(CO2) trapping studies on R. capsulatus DXS performed by Eubanks and Poulter suggested an 
ordered sequential kinetic mechanism. [19]  The results of the experiment indicated that pyruvate 
bound first and irreversibly, followed by binding of GAP to form a ternary complex, and, finally, 
the release CO2 and DXP in that order.  However, subsequent work demonstrating that DXS will 
catalyze the conversion of pyruvate to acetolactate and CO2 at high pyruvate concentrations 
suggests that the kinetic mechanism for R. capsulatus DXS is not sequential. [20-21] 
The third potential mechanism that DXS could display is a random sequential 
mechanism, in which binding of both substrates is reversible and independent.  Brammer et al.[20, 
22] has proposed an unprecedented rapid equilibrium, random sequential mechanism for E. coli 
DXS, which is in contrast to all known TPP-dependent enzymes to date. Binding of either 
pyruvate or GAP is independent of the other, and GAP is required for the release of CO2 and the 
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formation of a kinetically competent ternary structure.  They suggest formation of the lactyl-TPP 
intermediate is the overall rate limiting step and it is maintained in a low-reactive state.  GAP 
binding induces a reorientation to provide the optimal dihedral angle for decarboxylation. [23] 
We report, herein, on the successful production of recombinant, catalytically active forms 
of Plasmodium falciparum DXS and Plasmodium vivax DXR.  Similar to earlier work on the 
expression of P. vivax DXS [24] and P. falciparum DXR,[25] the catalytically active forms of P. 
falciparum DXS and P. vivax DXR have been truncated to their respective catalytic cores, 
lacking the signaling and transit peptide for each of these enzymes.  In addition to recombinant 
P. falciparum DXS and P. vivax DXR, we also produced the truncated forms of P. vivax DXS 
and P. falciparum DXR in E. coli by following publication protocols.  Both P. falciparum and  
P. vivax DXS enzymes were characterized via steady-state kinetic analyses, intrinsic tryptophan 
fluorescence titrations, and dead-end inhibition studies employing a pair of pyruvate mimics.  
DXS activity was measured using a DXR-dependent coupled assay, pairing P. falciparum DXS 
with P. falciparum DXR or P. vivax DXS with P. vivax DXR.  Our characterization of DXS 
from two Plasmodium species points toward a random sequential kinetic mechanism, an 
unexpected finding for TPP-dependent enzymes.  This work fosters a deeper understanding of 
the DXS-catalyzed reaction and will aid in the rational design of DXS inhibitors for the 
treatment of malaria and other human diseases. 
 
4.2 Experimental Procedures 
4.2.1 Materials and General Methods 
Unless otherwise noted, all reagents were obtained from commercial sources. BL21 
(DE3) E. coli cells and the pET-28a (+) vector were purchased from Novagen.  PfuUltra 
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High-Fidelity DNA polymerase was purchased from Agilent.  BamHI, XhoI, NdeI, Antarctic 
Phosphatase, and T4 DNA ligase were purchased from New England Biolabs. Kanamycin 
monosulfate and IPTG were purchased from Gold Biotechnology.  Size exclusion 
chromatography was performed on a GE Healthcare AKTAprime Plus FPLC, coupled to a 
HiLoad 16/600 Superdex 200 pg column.  Spectrophotometric analyses were performed on a 
Cary 300 Bio UV-Visible spectrophotometer.  Tryptophan fluorescence studies were performed 
on a JASCO FP-8300 spectrofluorometer.  
 
4.2.2 Cloning of the P. falciparum dxs and P. vivax dxr Genes Without Signal and Transit 
Peptides 
A synthetic, codon-optimized gene for P. falciparum dxs was purchased from Genscript.  
P. falciparum dxs was designed with 5’-NdeI and 3’-XhoI restriction sites and synthesized into a 
pUC57 vector.  The full-length gene was excised from the pUC57 vector and cloned into the 
NdeI and XhoI restriction sites of the pET-28a vector.  Similarly, a P. vivax dxr codon-optimized 
gene was also purchased from Genscript, with 5’-NdeI and 3’-BamHI restriction sites in a 
pUC57 vector.  P. vivax dxr was cloned into pET-28a using NdeI and BamHI restriction sites.   
Truncated gene constructs were produced from the full length, codon-optimized genes 
using PCR extraction to eliminate expression of the N-terminal signal and transit peptides of 
both PfDXS and PvDXR.  PfDXS-A, PfDXS-B, PfDXS-C, and PfDXS-D were produced with 
deletions of 237, 286, 292, and 310 amino acids, respectively.  PvDXR-E, PvDXR-F, and 
PvDXR-G were constructed with 99, 106, and 110 amino acid deletions, respectively.  The 
cloning of PvDXS was described previously.[24] The cloning of PfDXR has also been previously 
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described,[25] and this gene was generously donated by Dr. Nobutada Tanaka at Showa 
University (Japan) for the use in this study. 
4.2.3 Overexpression of Truncated DXS and DXR Proteins in E. coli 
Truncated gene transcripts of DXS and DXR in pET-28a were transformed into E. coli 
BL-21 (DE3) cells.  A fresh colony of cells harboring either truncated Pfdxs-pET-28a or Pvdxr-
pET-28a were inoculated at 37°C in LB broth containing 40 µg/mL kanamycin supplemented 
with 0.8% glucose and 25 mM potassium phosphate (pH = 7.2).  The cultures were grown until 
the OD600 reached 0.3, then diluted 1:100.  For the overexpression of PfDXS, cells were cultured 
until the OD600 reached 0.6, the temperature reduced to 10°C, induced by the addition of  
0.5 mM IPTG, and incubated overnight (12 hours) with continuous shaking. To produce PvDXR, 
the temperature was dropped to 30°C after achieving an OD600 of 0.6, induction initiated with  
1 mM IPTG, and overnight incubation.  Cells were harvested by centrifugation, and the cell 
pellets stored at -80°C.  The expression of PvDXS[24] and PfDXR[25] were described previously.   
 
4.2.4 Purification of DXS and DXR by Ni-NTA Affinity and Size-Exclusion 
Chromatography 
Cells were thawed on ice and all purification steps were performed at 4°C.  Cell pellets (4 
g) were resuspended in 20 mL of binding buffer supplemented with protease inhibitors: 20 mM 
Tris pH 7.5, 500 mM NaCl, 20 mM imidazole, 10 mM b-mercaptoethanol (BME), 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 4 mg/mL leupeptin, 2 mg/mL pepstatin, and 43 mg of an 
E. coli-specific protease inhibitor cocktail (Sigma P8465).  The cells were lysed via sonication, 
centrifuged at 16,000 x g for 20 minutes at 4°C, and the recombinant enzyme-containing soluble 
lysate was retained.    
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Purification of DXS and DXR was facilitated by the fusion of an N-terminal His6-tag to 
the active, truncated enzymes.  The supernatant was applied to a borosilicate glass column  
(1.5 cm × 5 cm) containing 5 mL of nickel-nitrilotriacetic acid (Ni-NTA) resin equilibrated with 
binding buffer.  The non-bound proteins were first eluted with 5 column volumes (CVs) of 
binding buffer, then with 20 CVs of wash buffer (20 mM Tris pH 7.5, 500 mM NaCl,  
60 mM imidazole, and 10 mM BME) at a flow rate of 1 mL/minute.  Tagged, recombinant 
enzyme was eluted with 2 CVs of elution buffer (20 mM Tris pH 7.5, 500 mM NaCl, 250 mM 
imidazole, 10 mM BME) and concentrated to <3 mL using an Amicon stirred ultrafiltration cell 
in preparation for size exclusion chromatography (SEC). The concentrated sample was injected 
onto an AKTAprime FPLC coupled to a 16/600 Superdex column equilibrated with 50 mM Tris 
pH 7.5, 150 mM NaCl, and 10 mM BME.  The flow rate for the SEC was set to 1 mL/min with a 
maximum pressure of 0.5 mPa.  The concentration of the enzyme-containing fractions was 
determined using the Bradford assay and purity was assessed by a 10% SDS-PAGE gel 
visualized with Coomassie Brilliant Blue stain.  Fractions containing purified enzyme were 
combined, glycerol added to a final concentration of 10% (w/v), and the aliquots were flash 
frozen in liquid nitrogen with subsequent storage at -80°C. 
 
4.2.5 Kinetic Analyses 
DXS activity from both P.  falciparum and P. vivax was measured spectrophotometrically 
using DXR from its corresponding organism as a coupling enzyme as previously reported [26] 
with minor variations.  The concentration of D-GAP was determined enzymatically from 
commercially available D,L-GAP using human GAPDH. [21]  Throughout the manuscript, our 
use of “GAP” refers to the concentration of D-GAP in the D,L-GAP mixture.  Reaction mixtures 
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containing 100 mM HEPES pH 7.0, 100 mM NaCl, 1.5 mM MgCl2, 1 mg/mL BSA, 1 mM TPP, 
2 mM BME, 150 μM NADPH, GAP, and pyruvate were preincubated for 5 minutes at 37°C.  
DXR was pipetted into the cuvette (0.2 mg/mL), 100 nM of DXS was added to initiate the 
reaction, and the solution (750 L total volume) was vigorously mixed before initializing the 
spectrophotometer software.  Rates of NADPH consumption in the coupled step between DXS 
and DXR were monitored spectrophotometrically at 340 nm for 2 minutes (extinction 
coefficient of 6,220 M–1 cm–1 for NADPH).  The rates of NADPH depletion were used to 
calculate initial rates of DXP formation.  The apparent kinetic constants were determined by 
fitting the resulting data to equation 4.1 using SigmaPlot 12.0: vo represents initial velocity, 
Vmax,app is the apparent maximal velocity, Km,app is the apparent Michaelis constant, and [S] is the 
substrate concentration.  Assays were performed in triplicate and the uncertainty for the kcat,app 
and (kcat/Km)app values were calculated using equation 4.2, where σ is the standard error.[27] 
 
Equation 4.1 
vo =  
Vmax,app[S]
Km,app + [S]
 
 
Equation 4.2 
σ (
x
y
) =
x
y
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σx
x
)
2
+ (
σy
y
)
2
 
To delineate between a sequential and classic ping-pong mechanism, double-reciprocal 
plots of the initial velocity data were generated for GAP and pyruvate in SigmaPlot 12.0.  
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Non-linear regression analysis of initial rates and model discrimination analyses were performed 
in WaveMetrics IGOR Pro 6.  Initial velocities were determined by varying the concentration of 
one substrate, while holding the other substrate at a fixed concentration.  GAP was evaluated 
between 3.5 μM and 16 μM, whereas pyruvate was tested at concentrations ranging from 50 μM 
to 250 μM.  The resulting initial velocity data was fit to equation 4.3 for a rapid-equilibrium 
random Bi-Bi mechanism, where vo is the initial velocity, Vmax is the maximal velocity, [A] is 
the concentration of substrate A, [B] is the concentration of substrate B, Kia is the dissociation 
constant for substrate A, Kb is the Michaelis constant for substrate B, and Ka is the Michaelis 
constant for substrate A. 
 
Equation 4.3 
vo =
Vmax[A][B]
KiaKb + Ka[B] + Kb[A] + [A][B]
 
 
4.2.6 Synthesis of Methylacetylphosphonate (MAP) 
MAP was synthesized, as previously reported, [20, 28-30] with minor variations.  In a dry 
three-necked round bottom flask with a magnetic stir bar under positive N2 pressure, acetyl 
chloride (1.21 mL, 14 mmol, 1 eq) was cooled to 0°C in an ice-water bath. Trimethyl phosphite 
(1.65 mL, 14 mmol, 1 eq) was slowly injected over a period of 3 hours, which resulted in 
evolution of MeCl. After full addition of trimethyl phosphite, the light-grey solution was allowed 
to warm to room temperature and stirred for an additional 8 hours. Unreacted reagents were 
removed under vacuum to afford acetylphosphonate dimethyl ester (DAP). 1.58 g recovered 
(10.4 mmol, 74% yield) as a pale grey oil. 1H NMR (400 MHz, CDCl3) δ 2.24 (d, J = 5.31 Hz, 
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3H, CH3), 3.61 (d, J = 10.69, 6H, OCH3). 13C NMR (400 MHz, CDCl3): d= 208.1  
(d, JP,C=169.8 Hz), 54.0 (d, 2JP,C=7.2 Hz, 2 C), 20.9 (d, 2JP,C=36.0 Hz). 
The recovered DAP (1.58 g, 10.4 mmol, 1 eq) was dissolved in dry acetone (10.4 mL), 
and the solution was slowly injected into a solution of sodium iodide (1.71 g, 11.5 mmol, 1.1 eq) 
in 6 mL dry acetone.  The yellow reaction mixture was stirred overnight at room temperature 
after which the precipitate was filtered, triturated with dry acetone, and dried to yield purified 
MAP.  93% yield.  1H NMR (400 MHz, D20) δ 2.20 (3 H, d, J 9.8 Hz) and 3.69 (3 H, d, J 10.63 
Hz).  All NMR spectra of isolated compounds are in agreement with literature reports. 
 
4.2.7 Inhibition of DXS with β-Fluorpyruvate and Methylacetylphosphonate 
The varying inhibition patterns of DXS activity were measured with the DXS-DXR 
coupled assay in the presence of either β-fluoropyruvate or methylacetylphosphonate (MAP). 
Inhibitor concentrations were based upon previously established IC50 values (data not shown) 
and added to the kinetic reaction mixtures described above.   For PvDXS, the concentrations of 
β-fluoropyruvate tested were 0, 35, and 75 μM, while MAP was analyzed at 0, 150, and 300 μM.  
To test PfDXS inhibition, β-fluoropyruvate and MAP concentrations were held at 0, 50, 100 μM 
and 0, 70, 140 μM, respectively.  No inhibition of DXR by either inhibitor was observed.  All 
assays were performed in triplicate, and the resulting data was fit to equations 4.4 – 4.6 in 
SigmaPlot 12.0 for competitive, noncompetitive, and uncompetitive inhibition, respectively.  For 
equations 4.4 – 4.6, vo is the initial velocity, Vmax,app is the apparent maximal velocity, Km,app is 
the apparent Michaelis constant, [S] is the substrate concentration, [I] is the inhibitor 
concentration, and Ki is the inhibition constant.   
Equation 4.4 
89 
 
vo =
Vmax,app[S]
Km,app (1 +
[I]
Ki
) + [S]
 
Equation 4.5 
vo =
Vmax,app[S]
Km,app (1 +
[I]
Ki
) + [S] (1 +
[I]
Ki
)
 
 
Equation 4.6 
vo =
Vmax,app[S]
Km,app + [S] (1 +
[I]
Ki
)
 
4.2.8 Intrinsic Tryptophan Fluorescence Measurements for the Determination of Binding 
Constants for DXS 
To study the binding of pyruvate and GAP to DXS, intrinsic tryptophan fluorescence 
(ITF) quenching titrations were utilized.  All reaction mixtures for ITF titrations contained 100 
mM HEPES pH 7.0, 100 mM NaCl, 1.5 mM MgCl2, 2 mM BME, and 500 nM DXS in a final 
volume of 400 L. Fluorescent emission spectra were acquired on a JASCO FP-8300 
spectrofluorometer at 25°C.  The excitation wavelength was set at 280 nm, and emission 
occurred between 290-300 nm.  Spectra were measured in triplicate from 305 nm to 360 nm, 
using a scan speed of 50 nm/min, and both excitation and emission bandwidth set at 2.5 nm.  
Spectra were corrected by subtracting emission spectra from acquisitions containing no enzyme 
(blanks), and normalized by taking the ratio of the fluorescence intensity at the λmax relative to 
starting enzyme only samples.  Data were fit to equation 4.7, where ΔF is the change in intrinsic 
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fluorescence, ΔFmax is the maximum change of fluorescence at infinite ligand concentration,  
[L] is the ligand concentration, and Kd is the ligand dissociation constant.   
Equation 4.7  
∆F =  
∆Fmax[L]
Kd + [L]
 
 
4.3 Results and Discussion 
Malaria parasites and other infectious organisms of the phylum Apicomplexa possess the 
apicoplast, an endosymbiotic organelle similar to the chloroplast of plants and algae. [31]  With a 
complete genome producing nearly 400 assorted proteins, the apicoplast is vital in various 
aspects of parasite metabolism including fatty acid and isoprenoid biosynthesis. All of the 
enzymes from the non-mevalonate pathway are nuclear-encoded and translocated to the 
apicoplast through a secretory pathway utilizing a bipartite N-terminal signaling motif.  This 
sequence consists of two functional domains: an endoplasmic reticulum-targeting signal peptide 
and a transit peptide.  The signal peptide directs the translocation of the enzyme into the 
secretory pathway, while the transit peptide facilitates the movement through the four outer 
membranes of the apicoplast.  Once inside, the peptides are cleaved off (most likely by a stromal 
processing protease) to yield the catalytically-competent enzyme. [32] 
To date, only a few enzymes targeted to the apicoplast from Plasmodium have been 
expressed, due in part to difficulties in obtaining soluble recombinant enzyme from E. coli host 
cells. [24, 33-34]  In addition to codon biases between E. coli and Plasmodium species (high GC 
content, ribosomal binding sites, random repeats of rare codons, etc), the presence of the 
signaling and transit motifs consistently result in the accumulation of insoluble inclusion bodies. 
[33]  Therefore, serial deletion of the full-length, untruncated gene is required to produce a DXS 
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or DXR variant that is soluble when expressed in E. coli.  Several freely available algorithms 
(PlasmoAP [35], PATS [36], PSORT [37], etc.) have been developed, which have proven successful 
in identifying the signal peptide.  Note that the signal peptide varies in length from 20-30 amino 
acids and exhibits a consensus sequence.  In contrast, there is no consensus sequence or narrowly 
defined size for the transit peptide, which can vary from 50-500 amino acids, meaning that there 
are no current algorithms that can accurately predict this peptide region (see Figure 4.1 of the 
DXS amino acid sequence from several organisms with low N-terminal homology).  Malarial 
transit peptides can be approximated by the presence of highly enriched lysine and asparagine 
residues, which results in an overall positive charge. [35] This trend is pronounced in the amino 
acid sequence of P. falciparum DXS between residues ~150-300 (Figure 4.1, note the high 
number of successive asparagine residues).  
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Homology overlays of the N-terminal amino acid sequence for Plasmodium vivax, 
Plasmodium knowlesi, Plasmodium cynomolgi and Plasmodium falciparum. 
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By utilizing homology modeling and N-terminal serial deletions of the full-length codon-
optimized genes, several targeted variants of PfDXS and PvDXR were produced in our 
expression optimization study.  PfDXS-A, PfDXS-B, PfDXS-C, and PfDXS-D were generated 
with N-terminal deletions of 237, 286, 292, and 310 amino acids, respectively.  PvDXR-E, 
PvDXR-F, and PvDXR-G were constructed with N-terminal deletions of 99, 106, and 110 amino 
acid deletions, respectively.  Each of these genes was then transformed into BL-21 (DE3) E. coli 
expression cells, and cultured in 2 mL aliquots.  These small-scale cultures were optimized for 
time of expression (1, 3, 5, and 12 hours), induction temperature (10, 25, 30, or 37°C) and IPTG 
concentration (0.1, 0.5, or 1.0 mM) for a total of 48 culture conditions per truncated gene.  The 
small scale cultures were then centrifuged, lysed via sonication, and the soluble proteome 
subjected to an anti-6His Western blot antibody assay for the detection of recombinant enzyme.  
Only one truncated gene and one set of variables proved successful for each enzyme:  PfDXS-D 
(with 310 amino acids deleted) was expressed at 10°C, induced by the addition of 0.5 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG), and incubated overnight (12 hours) with 
continuous shaking. After subsequent purification via Ni-NTA affinity and size exclusion 
chromatography, the final yield of PfDXS-D was 1.4 mg/L (Figure 4.2).   
To produce PvDXR, the protein construct with 110 amino acids removed (PvDXR-G) 
produced soluble enzyme at 30°C with 1 mM IPTG and overnight incubation.  PvDXR-G 
yielded 0.9 mg/L after both affinity and size exclusion chromatography (Figure 4.3).  This 
enzyme was used in the DXS-DXR coupled assay to further study PvDXS (kinetic constants of 
PvDXR-G: Km = 48 ± 1.6 μM, Vmax = 1.3 ± 0.01 s-1, kcat/Km = (2.7 ± 0.1) x 104 M-1s-1. These 
values are in good agreement with previously published data for DXR from several other 
organisms. [38-41]  The cloning, expression, and characterization of PfDXR [25] and PvDXS [24] 
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were previously described.  From this point forth, PfDXS-D and PvDXR-G will simply be 
referred to as PfDXS and PvDXR, respectively. 
 
 
 
 
 
 
Figure 4.2 Purification scheme of Plasmodium falciparum DXS.   
(A) Size-exclusion chromatography elution profile versus enzymatic activity. 
 (B) SDS-PAGE of the purification workflow 
  1) Molecular weight ladder 
  2) Nickel-column binding fraction 
  3) Nickel-column wash fraction 
  4) Nickel-column elution fraction 
  5) Size-exclusion column load 
  6) Size-exclusion column -purified PfDXS 
  7) MagicMark XP Western blot molecular weight ladder 
 (C) Western blot of the purification workflow 
  1) Molecular weight ladder 
  2) Nickel-column binding fraction 
  3) Nickel-column wash fraction 
  4) Nickel-column elution fraction 
  5) Size-exclusion column load 
  6) Size-exclusion column -purified PfDXS 
  7) MagicMark XP Western blot molecular weight ladder 
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Figure 4.3  Purification scheme of Plasmodium vivax DXR.  
 (A) Same as A above 
 (B) Same as B above 
 (C) Same as C above 
 
Once both sets of enzymes were cloned, expressed, and purified, we set about to 
elucidate kinetic and binding characteristics of DXS from P. falciparum and P. vivax. For the 
determination of kinetic constants, initial velocities of DXP formation were monitored using the 
DXS-DXR coupled assay at sub-saturating concentrations of one substrate, while holding the 
other fixed.  Rates were determined in triplicate.  Binding constants were obtained using intrinsic 
tryptophan fluorescence titrations, and the results of both of these experiments are detailed in 
Table 4.1. 
The kinetic constants for both P. falciparum DXS and P. vivax DXS are comparable to 
previously published data for DXS from E. coli, R. capsulatas, and D. radiodurans.  The Kd 
values for both Plasmodium enzymes are also commensurate with the dissociation constants for 
E. coli DXS (see Figures 4.4 and 4.5).  Clues of the binding mechanism can be delineated from 
these data:  in the ordered mechanism with pyruvate binding first and, irreversibly, binding of 
pyruvate to DXS will induce a conformational change that promotes binding of GAP.  Binding 
of GAP to free enzyme should, therefore, be negligible. [20]  However, a measurable binding 
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constant for pyruvate to both PfDXS and PvDXS suggests that pyruvate binding is, in fact 
reversible, inconsistent with an ordered mechanism. In the proposed ping-pong mechanism, GAP 
will have low affinity for the free enzyme.  However, again, we observed quenching of the 
fluorescent signal indicative of GAP binding reversibly to both of the Plasmodium DXS 
enzymes. These data are inconsistent with a ping-pong mechanism. Taken together, the ITF data 
supports a random sequential mechanism where GAP and pyruvate can both bind reversibly and 
independently to either P. falciparum or P. vivax DXS.  
Also noted in our ITF data is an apparent Stokes shift in the wavelength for maximum 
fluorescence intensity when DXS is incubated with high concentrations of GAP, which was not 
found at similarly high levels of pyruvate (Figures 4.4 and 4.5).  Tryptophan fluorescence is 
commonly used to monitor perturbations in protein dynamics and localized structures; 
fluorescence from tryptophan is sensitive to the polarity of its local environment. [42]  Therefore, 
this apparent Stokes shift suggests that GAP binding induces a conformation change in DXS, at 
least within the vicinity of the fluorescent tryptophan residue.  This represents the first report of a 
conformational change in DXS upon substrate binding.  Additional data for other DXS enzymes 
is required to determine the significance of our observation. 
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Table 4.1 Binding Constants and Steady-State Kinetic Constants of DXS from several organisms 
 
 
 
 
 
 
 
 
 
 
References: 
1. This study 
2. Brammer, L. A.; Smith, J. M.; Wade, H.; Meyers, C. F., 1-Deoxy-D-xylulose 5-Phosphate Synthase Catalyzes a Novel 
Random Sequential Mechanism. Journal of Biological Chemistry 2011, 286 (42), 36522-36531. 
3. Eubanks, L. M.; Poulter, C. D., Rhodobacter capsulatus 1-deoxy-D-xylulose 5-phosphate synthase: Steady-state kinetics and 
substrate binding. Biochemistry 2003, 42 (4), 1140-1149. 
4. Handa, Sumit, "1-deoxy-D-xylulose-5-phosphate Synthase (DXS) Mechanistic Study and its Implication in the Development 
of Novel Antibiotics and Antimalarials" (2012). Graduate Theses and Dissertations.  
<http://scholarcommons.usf.edu/etd/4063> 
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Reference 
P. falciparum 640 ± 16  
2600 ± 
650  
4.2 ± 0.03  
(6.5 ± 0.2) x 
10
3
  
16 ± 2.3  
4100 ± 
1200 
4.1 ± 0.17  
(2.5 ± 0.4) 
× 10
5
  
1  
P. vivax  1090 ± 60  770 ± 210  6.6 ± 0.15  
(6.1 ± 0.4) x 
10
3
  
26 ± 2.6  
2300 ± 
1300 
6.4 ± 0.22 
(2.4 ± 0.3) 
× 10
5
  
1 
E. coli  49 ± 8.0  230 ± 70  2.6 ± 0.11  5.3 x 10
4
  24 ± 1.7  
2000 ± 
500  
2.6 ± 0.11  1.1 × 10
5
  2 
R. capsulatus 440 ± 50  --  1.9 ± 0.10  4.3 x 10
3
  68 ± 1.0  --  1.9 ± 0.10  2.8 × 10
4
  3 
D. radiodurans 280 ± 30  --  7.4 ± 0.30  2.6 x 10
4
  50 ± 10.0  --  7.9 ± 0.40  1.5 × 10
5
  4 
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Figure 4.4 Substrate-binding analysis of PvDXS by intrinsic-tryptophan quenching titrations 
with increasing [pyruvate] and [GAP]. 
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Figure 4.5 Substrate-binding analysis of PfDXS by intrinsic-tryptophan quenching titrations 
with increasing [pyruvate] and [GAP]. 
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Double-reciprocal plots were generated to differentiate between a sequential binding 
mechanism and a ping-pong mechanism for both of the DXS enzymes from Plasmodium 
(Figures 4.6 and 4.7).  The Lineweaver-Burk plots for both GAP and pyruvate had 
noncompetitive pattern with changes in both slope and intercept, suggesting a random sequential 
mechanism.  If substrate binding to DXS were ordered, a competitive pattern for GAP would 
result and an uncompetitive pattern for pyruvate would be observed.  Substrate inhibition was 
found at higher concentrations of both pyruvate and GAP (as evidenced by the converging lines), 
similar to what was reported by Brammer, et al.[20] for E. coli DXS.  The data was further 
evaluated using global non-linear regression analysis: several mechanistic models for a two 
substrate, two product (Bi Bi) system were examined in a model discrimination analysis (rapid-
equilibrium ordered, rapid-equilibrium random, ping-pong, etc).  The data were best fit to the 
equations for a random sequential mechanism (Figures 4.8 and 4.9).   
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Figure 4.6 PvDXS double-reciprocal plots of initial velocities for pyruvate and GAP.  
(A) Velocities measured at fixed concentrations of GAP: 0.016 mM (), 0.008 mM (), 0.005 
mM (), 0.0035 mM ().  (B) Velocities measured at fixed concentrations of pyruvate: 0.25 
mM (), 0.15 mM (), 0.10 mM (), and 0.05 mM (). 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 PfDXS double-reciprocal plots of initial velocities for pyruvate and GAP. (A) 
Velocities measured at fixed concentrations of GAP: 0.016 mM (), 0.008 mM (), 0.005 mM 
(), 0.0035 mM ().  (B) Velocities measured at fixed concentrations of pyruvate: 0.25 mM 
(), 0.15 mM (), 0.10 mM (), and 0.05 mM (). 
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Figure 4.8 PvDXS global non-linear regression analysis for a random sequential mechanism. 
Velocities measured at fixed concentrations of GAP: 0.016 mM (), 0.008 mM (), 0.005 mM 
(), 0.0035 mM ().  (B) Velocities measured at fixed concentrations of pyruvate: 0.25 mM 
(), 0.15 mM (), 0.10 mM (), and 0.05 mM ().  
 
 
 
 
 
 
 
 
Figure 4.9 PfDXS global non-linear regression analysis for a random sequential mechanism. 
Velocities measured at fixed concentrations of GAP: 0.016 mM (), 0.008 mM (), 0.005 mM 
(), 0.0035 mM ().  (B) Velocities measured at fixed concentrations of pyruvate: 0.25 mM 
(), 0.15 mM (), 0.10 mM (), and 0.05 mM (). 
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Finally, inhibition studies were conducted to further confirm the mechanism of substrate 
binding to DXS.  Both β-fluoropyruvate and MAP have been previously used as pyruvate 
mimics to study TPP-dependent enzyme mechanisms. [28, 43-45] After TPP activation,  
β-fluoropyruvate undergoes a catalytic step to release CO2 with consequent elimination of 
fluoride; therefore, it is not representative of a true dead-end inhibitor against pyruvate.  MAP 
cannot undergo decaboxylation, and is, accordingly, a more suitable pyruvate analog. [20] Initial 
rates of DXP production were monitored using the DXS-DXR coupled assay at sub-saturating, 
varied concentrations of one substrate at fixed concentrations of the second substrate, in the 
presence of either inhibitor at varied concentrations. The equations for competitive, 
noncompetitive, and uncompetitive inhibition were fit to the data, and the results of the best fits 
are shown in Figures 4.10 and 4.11.  For the pair of DXS enzymes, both MAP and β-
fluoropyruvate displayed competitive inhibition against pyruvate, while exhibiting 
noncompetitive inhibition versus GAP (Table 4.2). This pattern of results is most consistent 
random sequential binding mechanism for both substrates to DXS.  Conversely, a ping-pong 
mechanism would yield an uncompetitive pattern with respect to GAP.  Unfortunately, the 
absence of a dead-end competitive inhibitor against GAP, precludes a definitive determination of 
the kinetic mechanism for the Plasmodium DXS enzymes included in our study, an impediment 
noted by several other groups. [19] 
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Figure 4.10 Inhibition of DXS by β-fluoropyruvate. (A) PvDXS assayed with varied 
concentrations of pyruvate at fixed concentrations of GAP (26 μM), in the presence of  
β-fluoropyruvate: 0 μM (), 35 μM (), and 75 μM ().  (B) PvDXS assayed with varied 
concentrations of GAP at fixed concentrations of pyruvate (1.1 mM), in the presence of  
β-fluoropyruvate: 0 μM (), 35 μM (), and 75 μM (). (C) PfDXS assayed with varied 
concentrations of pyruvate at fixed concentrations of GAP (16 μM), in the presence of  
β-fluoropyruvate: 0 μM (), 50 μM (), and 100 μM (). (D) PfDXS assayed with varied 
concentrations of GAP at fixed concentrations of pyruvate (640 μM), in the presence of  
β-fluoropyruvate: 0 μM (), 50 μM (), and 100 μM (). 
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Figure 4.11 Inhibition of DXS by MAP. (A) PvDXS assayed with varied concentrations of 
pyruvate at fixed concentrations of GAP (26 μM), in the presence of MAP: 0 μM (), 150 μM 
(), and 300 μM ().  (B) PvDXS assayed with varied concentrations of GAP at fixed 
concentrations of pyruvate (1.1 mM), in the presence of MAP: 0 μM (), 150 μM (), and 300 
μM (). (C) PfDXS assayed with varied concentrations of pyruvate at fixed concentrations of 
GAP (16 μM), in the presence of MAP: 0 μM (), 70 μM (), and 140 μM (). (D) PfDXS 
assayed with varied concentrations of GAP at fixed concentrations of pyruvate (640 μM), in the 
presence of MAP: 0 μM (), 70 μM (), and 140 μM (). 
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Table 4.2 Inhibition constants for β-fluoropyruvate and MAP against PvDXS and PfDXS 
 
 
 
 
 
 
 
 
4.4 Conclusion 
The first two enzymes of the non-mevalonate pathway in the malaria-causing protists 
Plasmodium vivax and Plasmodium falciparum are DXS and DXR, respectively.  Catalytically 
active, truncated forms of all four enzymes have been cloned and over-expressed in E. coli:   
P. falciparum DXS (described herein), P. falciparum DXR by Umeda et al.[25], P. vivax DXS by 
Handa et al.[24], and P. vivax DXR (described herein).  Because of the metabolic centrality of the 
isoprenoids, the availability of DXS and DXR from P. falciparum and P. vivax should facilitate 
the development of novel anti-malarials targeted against either of these enzymes.  The kinetic 
mechanism for DXS has proven controversial, with the majority of the published data pointing 
towards a random sequential mechanism. [20, 22] Such a mechanism is unusual for a TPP-
dependent enzyme, as the first substrate typically forms an adduct with the thiazolium moiety of 
TPP. [16-17, 22] yielding either an ordered or ping-pong kinetic mechanism.  Our characterization 
of PfDXS and PvDXS, steady-state kinetic analyses, substrate binding studies, and dead-end 
inhibition experiments, are most consistent with a random sequential mechanism for both 
enzymes.  The expression of PfDXS and PvDXS in E. coli, providing straightforward access to 
Enzyme Inhibitor Substrate Pattern Ki app(μM) 
PvDXS  
β-fluoropyruvate 
Pyruvate  Competitive  35 ± 1.7 
GAP  Noncompetitive  77 ± 7.2 
MAP  
Pyruvate  Competitive  75 ± 5.0 
GAP  Noncompetitive  89 ± 6.7 
PfDXS  
β-fluoropyruvate 
Pyruvate  Competitive  43 ± 3.8 
GAP  Noncompetitive  131 ± 10 
MAP  
Pyruvate  Competitive  46 ± 3.8 
GAP  Noncompetitive  103 ± 7.2 
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multi-milligram amounts of protein and fostering the construction of site-directed mutants, will 
enable the detailed structure-function studies to better understand the unique aspects of TPP-
dependent chemistry of DXS. 
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Figure A.1 Bm-AANAT with 100 μM oleoyl-CoA and varied tryptamine. 
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Figure A.2 Bm-AANAT with 100 μM oleoyl-CoA and varied octopamine. 
 
 
 
Figure A.3 Bm-AANAT with 100 μM oleoyl-CoA and varied tyramine. 
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Figure A.4 Bm-AANAT with 100 μM lauroyl-CoA and varied tryptamine. 
 
 
 
 
Figure A.5 Bm-AANAT with 100 μM myristoyl-CoA and varied tryptamine. 
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Figure A.6 Bm-AANAT with 100 μM palmitoyl-CoA and varied tryptamine. 
 
 
 
 
Figure A.7 Bm-AANAT with 60 mM tryptamine and varied arachidonoyl-CoA. 
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Figure A.8 Bm-AANAT with 60 mM tryptamine and varied lauroyl-CoA. 
 
 
 
Figure A.9 Bm-AANAT with 60 mM tryptamine and varied myristoyl-CoA. 
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Figure A.10 Bm-AANAT with 60 mM tryptamine and varied oleoyl-CoA. 
 
 
 
 
Figure A.11 Bm-AANAT with 60 mM tryptamine and varied palmitoyl-CoA. 
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Figure A.12 Bm-AANAT3 with 500 μM acetyl-CoA and varied dopamine. 
 
 
 
 
Figure A.13 Bm-AANAT3 with 500 μM acetyl-CoA and varied histamine. 
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Figure A.14 Bm-AANAT3 with 500 μM acetyl-CoA and varied norepinephrine. 
 
 
 
 
Figure A.15 Bm-AANAT3 with 500 μM acetyl-CoA and varied octopamine. 
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Figure A.16 Bm-AANAT3 with 500 μM acetyl-CoA and varied serotonin. 
 
 
 
 
Figure A.17 Bm-AANAT3 with 500 μM acetyl-CoA and varied tryptamine. 
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Figure A.18 Bm-AANAT3 with 500 μM acetyl-CoA and varied tyramine. 
 
 
 
 
 
Figure A.19 Bm-AANAT3 with 8 mM tryptamine and varied acetyl-CoA.  
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Figure A.20 Bm-AANAT3 with 8 mM tryptamine and varied butyryl-CoA.  
 
 
 
Figure A.21 Bm-AANAT3 with 8 mM tryptamine and varied hexanoyl-CoA.  
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Figure A.22 Bm-AANAT3 with 8 mM tryptamine and varied octanoyl-CoA.  
 
 
 
Figure A.23 Bm-AANAT3 with 8 mM tryptamine and varied decanoyl-CoA.  
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Figure A.24 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 6.5) 
 
 
 
 
Figure A.25 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 7.0) 
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Figure A.26 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 7.5) 
 
 
 
Figure A.27 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 8.0) 
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Figure A.28 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 8.5) 
 
 
 
 
Figure A.29 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 9.0) 
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Figure A.30 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 9.5) 
 
 
 
 
Figure A.31 Bm-AANAT3 double reciprocal plot with varied tryptamine at constant 
concentrations of acetyl-CoA.  For data sets fit to global nonlinear regression analysis, see 
Figures 2.3A. 
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Figure A.32 Bm-AANAT3 double reciprocal plot with varied acetyl-CoA at constant 
concentrations of tryptamine.  For data sets fit to global nonlinear regression analysis, see 
Figures 2.3B. 
 
 
 
Figure A.33 Bm-AANAT3 E27A site-directed mutant with varied acetyl-CoA. 
 
130 
 
 
Figure A.34 Bm-AANAT3 E27A site-directed mutant with varied tryptamine. 
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Figure A.35 Bm-AANAT product characterization with LC/QTOF-MS.  Resulting N-
oleoyltryptamine from the Bm-AANAT-catalyzed reaction in vitro. 
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Figure A.36 Bm-AANAT product characterization with LC/QTOF-MS. Synthesized N-
oleoyltryptamine standard. 
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Figure A.37 Bm-AANAT product characterization with LC/QTOF-MS. No enzyme blank. 
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Bm-AANAT codon-optimized gene sequence: 
CATATGGCAGTCACCAGCACCCGTGGCATTGTCAACCTGAAAGAAAAAGGTCACTT
CGAACGCGAAAACGCTCGTGTGGAAAAATATACCCTGGGCGATGAACTGCCGGCTC
AGCTGAGCTCTCTGGAAATTCGTCCGCGCAAAATGAGCGTGCCGGCGTATACCATCC
AACGTCTGACGTACAACGATCGCGACCTGGTTCTGAAATTCCTGCGTCGCTTTTTCTT
TCGTGACGAACCGATGAACCTGGCCGTTAATCTGCTGGAAACCCCGGAATCTCGCTG
CACGGAACTGGATGACTATGCGGCCGCAACCCTGAGCGATGGCGTGTCTGTTGCTGC
GGTCGATGAAAACGGCGACTATGTCGGTGTGATTATCAATGGTATTGTTCGTCGCGA
AGAAGTCGATTACACCGACAAAAGCGAAGATTGTCCGAATCCGAAATTTCGTCGCA
TTCTGAAAGTGCTGGGCCATCTGGATCGTGAAGCCCGCATCTGGGACAAACTGCCGG
AAACCTGCGATAGTGTCCTGGAAATTCGTATCGCATCCACCCACAGTTCCTGGCGTG
GTCGCGGTCTGATGCGTGTGCTGTGTGAAGAAGCTGAACGCCTGGCCAAAGCAATG
GGTGCTGGTGCCCTGCGTATGGACACCACGTCAGCATTCTCGGCCGCAGCTGCGGAA
CGTCTGAACTATAAAATGGCCTTTGGTGTTCGCTACGCAGATCTGCCGTACGCCCCG
CAACCGGAAGCCCCGCACCTGGAAGCCCGTGTCTACATCAAAGAACTGTGACTCGA
G 
 
 
 
Bm-AANAT3 codon-optimized gene sequence: 
 
CATATGGCTGATTTTGTTGTTGTGATGCCGTCAATGAAAGATGCCGTTATCCAGCAC
CTGCGTGATTCCTTCTTTGCCGATGAACCGCTGAACAAAGCCGTGGGTCTGTGTGAA
CGTGGTCAGCCGCATGCCGCACTGGAACGTCTGTGTCTGGCAACCATGACGGATGG
CCTGTCCATTGCAGCTATGGATGGCGACAAAGTGCTGGGTGTTGCACTGAATGGCAT
TCTGCGTCACGGTGATATCGAACAGAGTATCGAAAAAATCAAACAATCCACCGACG
AAAAATTCAACAAAATCTTCAACATCCTGTATACCGTTAGCCGTGATCTGAACCTGT
TTAATACGTTCGAAGTCGACCTGATCATGGAATGCCGCATTATCAGCGTGCATGAAA
ACGCACGTGGCCGCGGTCTGGCTAAAGAACTGATGAAACGTTCTATTGATCTGGCGC
GCGACAACGAATTTAAACTGTTCAAAGTTGATGCGACCGGCGCCTTTAGTCAACGTA
TCTGCCGCAGCCTGTCTCTGGAAGAACTGAAATCAGTCCGCTATGATGAATACTGTG
ACGAATCGGGTACGCCGATCTTCCGTGTGCCGCCGCCGGACCATGCCCTGTGTGTTA
TGATTCTGAAACTGCCGTAACTCGAG 
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Figure B.1 Compound 2 proton NMR 
 
 
 
 
 
 
136 
 
 
Figure B.2 Compound 3 proton NMR 
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Figure B.3 Compound 4 proton NMR 
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Figure B.4 Compound 6 proton NMR 
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Figure B.5 Compound (Probe) 7 proton NMR 
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Figure C.1 Plasmodium vivax DXS steady-state kinetic constants with varied Pyruvate. 
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Figure C.2 Plasmodium vivax DXS steady-state kinetic constants with varied GAP. 
 
Figure C.3 Plasmodium facliparum DXS steady-state kinetic constants with varied Pyruvate. 
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Figure C.4 Plasmodium facliparum DXS steady-state kinetic constants with varied GAP 
 
 
Plasmodium vivax (Sal-1) DXS SH-2 variant (Truncated & codon-optimized):   
 
 
TATCCGACCTCCGCGACGCTGGGCAAAAAACTGTTCAACGTGAAAAACGAAGAAGG
TCAAACCGGCCGCGAACCGCAACTGTCTGGTGCGAACGAAAAAAGTGATGACAACC
GTGATCCGCCGAATCTGGATGCCCTGTTCGACCAGATCAACTCATACATCGATGTTG
AAAAATACCGCGACACCTACGGCGAAGAAATCTACCATAAAATGGTGAAACTGTAC
GTTCGTCGCGATGTCCCGGAAAACTATGAAGAACTGTTTTTCACCGAACCGACGGAA
AAATCGGTGGCCCTGGATGTTGACAAATACGATGAAGACCACTTTGAAAAACTGAT
GCGTGAAGAATTCCAGCGCAACGGTGTGCTGATCAAAAACATCAGTAAAGAATACT
ACCAAAAAGAAAACATCAAAAAAGTGCTGAAAGTTCTGAAATACCTGCCGCTGCTG
CGTCTGATCAACAATCCGTCCGATCTGAAAAAACTGAAAAAAGAATGCCTGCCGCT
GCTGGCACATGAACTGAAAATGTTCCTGTTTTTCATGGTGAACATCACCGGTGGCCA
CTTTTCCGCTGGCCTGTCACTGCTGGAAGTTCAGCTGCTGCTGCTGTACCTGTTTGAT
CATCCGCACGATGACGTTATTTATGACATCGGTCATCAAGCGTACGTCCACAAAATT
CTGACCGGCCGCAAACTGCTGTTCCTGAGTCTGCGTCGCAAAAAAGGTATTTGTGGC
TTTCTGAATATCTTCGAAAGCGCCTATGATAAATTTGGTGCAGGCCATAGTTCCACC
GCTCTGTCTGCGATTCAGGGTTTCTACGAAGCCGATTGGCAGGTTTGGCAATTTTGG
CGTAAACGCACCGCTCATCCGGAAGAACGTCTGACCACGTCAAGCGCCCATCCGGG
TGAAGAAGGCCCGACCCGTGCTGGCGAAAACCAGCAAGCGAGCCATCCGAATCGCG
GTGGCACCACGCAGCAATCAGCCTATCCGGGTCGTAACAATTCGGCAGATCATCTG
AACAAAGTGCACATTGCCATTATTGGTGATGGTGGTCTGACCGGTGGCATGGCCCTG
143 
 
GAAGCACTGAACTATATCTCGTTTCTGAATAGCAAAGTGCTGATTATCTACAACGAT
AATGGTCAGGTTTCTCTGCCGACGAATGCACCGTCGATTAGCGGTCATCGCCCGATT
GGCTCTATCAGTGATCATCTGCACTCCTTCCTGGCCCGTAAAAGCGGTAAAGGCGAA
TCTCAGCAAGCAAGTGGCACCAAGAAAAACAACATCTTCGAAAACCTGAACTACGA
TTACGTCCAGGTGCAAAACGGTAATGACACCGAAGCGCTGTTTAACGCTCTGAGCGC
GTTCAAAAAAGGCAAAATGAATCGCGCCACGGTCCTGCATGTGTGCACCTCGAAAA
CGAGCGATTTTATTAACGCGCGTGCCCCGATCACCGTTATGCATTCAATTAAGAAAA
ACGAAATCTTCCCGTTCTCCGAAGATGCTCTGTCACCGCACGGTAAAGAAGGCGAAT
CGGCGGGTCATACGGCACACGCTCAGGATGACCAAGCCAACCGCGGCAAATCAAAT
TTCGCTAAAGAACAGCAAGAAGATGCGAAAATTTTTAGCAAAGAAACCTTCACGGA
CGTGTTCACCGAAGAAATGCTGACGTACCTGGAACGTGATAAAAACGTTATCTTCAT
CAGTCCGGCCATGCTGGGTGGCAGCGGTCTGGTCAAAATTAGCGAAAAATATCCGG
ATAACGTTTACGACGTCGGCATCGCCGAACAGCATGCAGTTACCTTCGCGACGGCCA
TGGCAATGAACAAAAGCCTGAAAATCTACCTGTGTATCTACTCTACCTTCATGCAGC
GCGCGTATGATCAAATTATCCATGACCTGAACCTGCAGAAAGTGCCGCTGAAAGTTA
TTGTCGGTCGTTCCGGCCTGATCGGTGAAGATGGCGCGACCCACCAGGGTATTTACG
ACCTGACGTTCCTGGGCGCTCTGAACAATGCGTGCGTTATCTCCCCGTCAAATCAGG
TCGATCTGAAAAAAGCGCTGAAATTTTGTCATCACGACGTGAACCGCCCGGTGTTTG
TTCGTCTGCCGCGCATTAATACCTTCACGGAAGAATATCTGCGTGGTTACTTTCGTAT
CGGTGGCGGTGGCCAGGTTGGTTGGGAAGAAAGCAAAACCGGCGAAGATCCGCTGA
AAGAAGAACTGCAAACGTTTTTCGGTAAAGCGCGTGTGATTAAAATCAGTCCGGAA
GAGAAAAAACCGAACGAAGGCGGCAAGAAAAAAGTTGCCATTTTTAATATGGGCTC
CATGCTGTTCAACGTGCTGAATGCCATTGAAGCAATCGAAAAAGATCATCTGCTGGC
GTCTCGCTTTAGTTTCACCGTGGTTGACATGATTTTTCTGAACCCGATGGATAGCTCT
ATTGTCGACTATCTGATTGTGCGTAACAAACATGATGTGCACATCACCTACGAAGAC
AATACGGTTGGTGGCTTTTCTACCCACTTCAACAACTACCTGATCGGCAAAAACTAC
ATCTCGCGCCATCAGCTGAGCGTGCACAACATTTATCTGCCGAATGATCCGATCGAA
CATGCTACCTACGCGGAACAGCACGTCGATGTGAAAATGGACAGTTCCTCACTGGA
AAATCGCATCCGCTCCTTTCTGCAGGGTGGTGTTAGCAAC 
 
 
 
Plasmodium vivax (Sal-1) DXR (codon-optimized): 
 
ATGAAAGGGTCCATTTGTTTGCACACCCTGTTGTTGCTCGTCGGCATGCAGGAAATG
GGGGCCGGTCGTGTGTGCCCCCAACGTGGTGAGAGGAAAAGGGCGTACGTAATAAA
TATGAAACGGGGGAGCGTGCAGAATGGTGGAGCGAGGCGAGGGCTGTGGTCCGGG
CGGGTAAAGTTTAGGAAGCGGGAGGACCTCTCCCGTGGGGGCAGAGGCCCTGAGTG
CGCGGTGAACGCGGTGAACGCGGCCAGCGCGGCAAATAATGGCAACCCCGCTAACG
CCGCTAACGATGCTAACGCTTCTAACCCCTCTAACCGCGCTAACCGCGCTAACCCCG
CCAACTGCATCAACGTGGCCATCTTCGGGAGCAGCGGGAGCATCGGCGCGAACGCG
CTGGACGTGATTCGCGAGTGCAACCGAGTTGAGAGGCGCTTCAACGTGGAGGCCCT
GTACGTCAACAAAAGCGTGACCAAACTGTATGAACAGGCAAGGGAGTTTTTGCCAA
AGTATGTGTGCATCCACGATGAGTCAAAATATGAGGAATTAAAAATGTTGTTAAGA
AAAATAAAGGGATACAACCCAGAGATACTAGTGGGGGATGATGGCATGAAACAAA
TGTGCAGCAGCAACACACTAGACAGAATTATAATTGGGATCGACTCCTTCCATGGGT
144 
 
TATACTCAACCATATATGCAATTAAAAGCAATAAAATTATTGGGCTAGCGAATAAA
GAGTCAATCGTATCTGCAGGATTTTTTCTCAAAAAATTATTAACAAGTCATACAAAA
TCGTGCATTATTCCAGTGGACTCAGAACACAGTGCCATCTTCCAATGTTTGGATAAT
AACAAAGTTTTAAAAACGAAATGTCTGCAGGATAGCTTCTCCAAAGTGAATCAAAT
AAAAAAATTAATTTTATCCTCCTCAGGTGGCCCCTTTCAAAATGCCTCCCTTGATGA
GCTGAAAAAAGTAACCGCAGAAGATGCCCTCAAACATCCAAAGTGGAAAATGGGAC
CCAAAATAACCATCGACTCTGCAACTATGATGAACAAAGGGTTAGAGGTGATTGAG
GCTCATTTCCTCTTCGACGTAGATTACAATCATATAGAAATCCTTGTGCATAAGGAA
TGTATTCTCCATTCGTGCGTAGAATTTATAGACAAATCGGTTGTAAGCCAAATGTAC
CTCCCAGATATGAAGCTTCCAATTCTATATGCTTTGACTTGGCCTAATAGAATTGCTA
CAGAATTGCCGTCTCTTAATTTGGCTAGTACGTCTCCCCTTACATTTTACTCCCCCTC
ACTGGACCACTTCCCTTGTATCAAGCTGGCGTACCAGGCAGGTCGGCAGGGGAACTT
CTACCCAACTGTCCTCAACGCGGCCAACGAGGTGGCCAACAAACTATTTCTAAGTAA
CAAAATTGGCTACTTTGACATTGCCGCCATCATATCTGACGTTTTGGAGTCCTTCACG
CCGCAGGAGGTCTCCAACAACTGCGAGGATTTGATGCACCAAATTGGGGGCATCCA
CAAGTGGGCCGTCCGCAGGGCTGAGGAGGTGTACCGGGTGCGCTCCTCCGCAGCGC
AGTGA 
 
 
 
 
 
 
 
Plasmodium falciparum (3D7) DXS (codon-optimized): 
ATGATTTTTAATTATGTGTTTTTTAAGAACTTTGTACCAGTTGTTCTATACATTCTCCT
TATAATATATATTAACTTAAATGGCATGAATAATAAAAATCAAATAAAAACAGAAA
AAATTTATATAAAGAAATTGAATAGGTTGTCAAGGAAAAATTCGTTATGTAGTTCTA
AAAATAAAATAGCATGCTTGTTCGATATAGGAAATGATGATAATAGAAATACGACA
TATGGCTATAATGTGAATGTTAAAAATGATGATATTAATTCCTTACTAAAAAATAAT
TATAGTAATAAATTGTACATGGATAAGAGGAAAAATATTAATAATGTAATTAGTACT
AATAAAATATCTGGGTCCATTTCAAATATTTGTAGTAGAAATCAAAAAGAAAATGA
ACAAAAAAGAAATAAACAAAGATGTTTAACTCAATGTCACACTTATAATATGTCAC
ATGAACAGGACAAACTAGCTAATGATAATAATAGGAATAATAAAAAGAATTTTAAT
TTATTATTTATAAATTATTTTAATTTGAAACGAATGAAAAATTCTCTTCTAAATAAAG
ACAATTTCTTTTACTGTAAAGAAAAAAAATTGTCATTTCTGCATAAGGCCTATAAAA
AAAAAAATTGCACTTTTCAAAATTATAGTTTAAAAAGAAAATCTAATCGTGATTCAC
ATAAATTGTTTTCTGGAGAATTTGACGATTATACAAATAATAATGCTTTATATGAAT
CCGAAAAAAAAGAATACATTACACTAAATAATAATAATAAAAATAATAATAATAAA
AATAATGATAATAAAAATAATGATAATAATGATTATAATAATAATAATAGTTGTAAT
AATTTAGGAGAGAGATCCAATCATTATGATAATTATGGTGGAGATAATAATAATCCA
TGTAATAATAATAATGACAAATATGATATAGGAAAATATTTCAAACAGATTAATACC
TTTATTAATATTGATGAATATAAAACTATATATGGTGATGAAATATATAAAGAAATA
TATGAACTATATGTAGAAAGAAATATTCCTGAATATTATGAACGAAAATATTTTTCA
GAAGATATTAAAAAGAGTGTCCTATTTGATATAGATAAATATAATGATGTCGAATTT
145 
 
GAAAAAGCTATAAAAGAAGAATTTATAAATAATGGAGTTTATATTAATAATATAGA
TAATACATATTATAAAAAAGAAAATATTTTAATAATGAAAAAGATATTACATTATTT
CCCATTATTAAAATTAATTAATAATCCATCAGATTTAAAAAAGTTAAAAAAACAATA
TTTACCTTTATTAGCACATGAATTAAAAATATTTTTATTTTTTATTGTAAATATAACA
GGAGGTCATTTTTCCTCTGTTTTAAGCTCTTTAGAAATTCAATTATTATTATTGTATAT
TTTTAATCAACCATATGATAATGTTATATATGATATAGGACATCAAGCATATGTACA
TAAGATATTGACCGGAAGAAAACTATTATTTCTATCATTAAGAAATAAAAAAGGTAT
TAGTGGATTCCTAAATATTTTTGAAAGTATTTATGATAAATTTGGGGCTGGTCACAG
TTCCACTTCATTAAGTGCTATACAAGGATATTATGAAGCCGAGTGGCAAGTGAAGAA
TAAAGAAAAATATGGAAATGGAGATATAGAAATAAGTGATAACGCAAATGTCACGA
ATAATGAAAGGATATTTCAAAAAGGAATACACAATGATAATAATATTAACAATAAT
ATTAATAATAATAATTATATCAATCCTTCAGATGTGGTAGGAAGAGAAAATACGAAT
GTACCAAATGTACGAAATGATAACCATAACGTGGATAAAGTACACATTGCTATTATA
GGAGATGGTGGTTTAACAGGTGGAATGGCATTAGAAGCGTTAAATTATATTTCATTC
TTGAATTCTAAAATTTTAATTATTTATAATGATAACGGACAAGTTTCTTTACCAACAA
ATGCCGTAAGTATATCAGGTAATAGACCTATAGGTTCTATATCAGATCATTTACATT
ATTTTGTTTCTAATATAGAAGCAAATGCTGGTGATAATAAATTATCGAAAAATGCAA
AAGAGAATAACATTTTTGAAAATTTGAATTATGATTATATTGGTGTTGTGAATGGTA
ATAATACAGAAGAGCTCTTTAAAGTATTAAATAATATAAAAGAAAATAAATTAAAA
AGAGCTACTGTTCTTCATGTACGTACAAAAAAATCGAATGATTTTATAAATTCAAAG
AGTCCAATAAGTATATTGCACTCTATAAAGAAAAATGAGATTTTCCCTTTCGATACC
ACTATATTAAATGGAAATATTCATAAGGAGAACAAGATAGAAGAAGAGAAAAATGT
GTCTTCATCTACAAAGTATGATGTAAATAATAAGAATAATAAAAATAATGATAATA
GTGAAATTATAAAATATGAAGATATGTTTTCAAAAGAGACGTTCACAGATATATATA
CAAATGAAATGTTAAAATATTTAAAGAAAGATAGAAATATAATATTCCTATCTCCCG
CTATGTTAGGAGGATCAGGATTGGTTAAAATTAGTGAGCGTTATCCAAATAATGTAT
ATGATGTAGGTATAGCAGAACAACATTCTGTAACTTTCGCAGCAGCTATGGCAATGA
ATAAGAAATTAAAAATACAATTATGTATATATTCGACCTTTTTACAAAGAGCATATG
ATCAAATTATACATGATCTTAATTTACAAAATATACCTTTAAAGGTTATAATTGGAA
GAAGTGGATTAGTAGGAGAGGATGGGGCAACACATCAAGGTATATATGATTTATCT
TATCTTGGGACACTTAACAATGCATATATAATATCTCCAAGTAATCAAGTTGATTTG
AAAAGAGCTCTTAGGTTTGCTTATTTAGATAAGGACCATTCTGTGTATATACGTATA
CCCAGAATGAACATATTAAGTGATAAGTACATGAAAGGATATTTGAACATTCATATG
AAAAATGAGAGCAAAAATATCGATGTAAACGTGGATATAAACGATGATGTAGATAA
ATATAGTGAAGAATATATGGACGATGATAATTTTATAAAATCGTTTATTGGAAAATC
TAGAATTATTAAAATGGATAATGAAAATAATAATACAAATGAACATTATTCAAGCA
GAGGAGATACACAGACAAAAAAAAAAAAAGTTTGTATCTTTAACATGGGTAGTATG
CTTTTTAATGTAATTAATGCTATAAAAGAAATTGAAAAAGAACAATATATTTCACAT
AATTATTCTTTTTCAATTGTTGATATGATATTTTTAAATCCTTTAGATAAAAATATGA
TAGATCATGTAATAAAACAAAATAAACATCAATATTTAATTACTTATGAAGATAATA
CTATAGGTGGTTTTTCTACACATTTCAATAATTATTTAATAGAAAATAATTATATAAC
AAAACATAATTTATATGTTCATAATATTTATTTATCTAATGAGCCAATTGAACATGC
ATCTTTTAAGGATCAACAAGAAGTTGTCAAAATGGATAAATGTAGTCTTGTCAATAG
AATTAAAAATTATCTTAAAAATAATCCTACATGA 
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Plasmodium falciparum (3D7) DXR (codon-optimized): 
ATGAAGAAATATATTTATATATATTTTTTCTTCATCACAATAACTATTAATGATTTAG
TAATAAATAATACATCAAAATGTGTTTCCATTGAAAGAAGAAAAAATAACGCATAT
ATAAATTATGGTATAGGATATAATGGACCAGATAATAAAATAACAAAGAGTAGAAG
ATGTAAAAGAATAAAGTTATGCAAAAAGGATTTAATAGATATTGGTGCAATAAAGA
AACCAATTAATGTAGCAATTTTTGGAAGTACTGGTAGTATAGGTACGAATGCTTTAA
ATATAATAAGGGAGTGTAATAAAATTGAAAATGTTTTTAATGTTAAAGCATTGTATG
TGAATAAGAGTGTGAATGAATTATATGAACAAGCTAGAGAATTTTTACCAGAATATT
TGTGTATACATGATAAAAGTGTATATGAAGAATTAAAAGAATTGGTAAAAAATATA
AAAGATTATAAACCTATAATATTGTGTGGTGATGAAGGGATGAAAGAAATATGTAG
TAGTAATAGTATAGATAAAATAGTTATTGGTATTGATTCTTTTCAAGGATTATATTCT
ACTATGTATGCAATTATGAATAATAAAATAGTTGCGTTAGCTAATAAAGAATCCATT
GTCTCTGCTGGTTTCTTTTTAAAGAAATTATTAAATATTCATAAAAATGCAAAGATA
ATACCTGTTGATTCAGAACATAGTGCTATATTTCAATGTTTAGATAATAATAAGGTA
TTAAAAACAAAATGTTTACAAGACAATTTTTCTAAAATTAACAATATAAATAAAATA
TTTTTATGTTCATCTGGAGGTCCATTTCAAAATTTAACTATGGACGAATTAAAAAAT
GTAACATCAGAAAATGCTTTAAAGCATCCTAAATGGAAAATGGGTAAGAAAATAAC
TATAGATTCTGCAACTATGATGAATAAAGGTTTAGAGGTTATAGAAACCCATTTTTT
ATTTGATGTAGATTATAATGATATAGAAGTTATAGTACATAAAGAATGCATTATACA
TTCTTGTGTTGAATTTATAGACAAATCAGTAATAAGTCAAATGTATTATCCAGATAT
GCAAATACCCATATTATATTCTTTAACATGGCCTGATAGAATAAAAACAAATTTAAA
ACCTTTAGATTTGGCTCAGGTTTCAACTCTTACATTTCATAAACCTTCTTTAGAACAT
TTCCCGTGTATTAAATTAGCTTATCAAGCAGGTATAAAAGGAAACTTTTATCCAACT
GTACTAAATGCGTCAAATGAAATAGCTAACAACTTATTTTTGAATAATAAAATTAAA
TATTTTGATATTTCCTCTATAATATCGCAAGTTCTTGAATCTTTCAATTCTCAAAAGG
TTTCGGAAAATAGTGAAGATTTAATGAAGCAAATTCTACAAATACATTCCTGGGCCA
AAGATAAAGCTACCGATATATACAACAAACATAATTCTTCATAG 
 
 
. 
 
